Fact-checked by Grok 2 weeks ago

Emphysema

Emphysema is a progressive disease and a primary form of (COPD), characterized by the irreversible destruction of the alveoli—the tiny in the s responsible for —resulting in enlarged air spaces, , and reduced oxygen intake. This damage impairs and leads to persistent respiratory symptoms, making breathing increasingly difficult over time, with no known cure but treatments available to manage progression and symptoms. Globally, emphysema contributes to the burden of COPD, which affects an estimated 392 million people and ranks as the fourth leading cause of death worldwide, causing 3.5 million deaths in 2021. In the United States, more than 3 million individuals live with emphysema, predominantly those with a . The primary cause of emphysema is long-term exposure to irritants, with cigarette smoking accounting for 80-90% of cases, typically manifesting symptoms after 20 pack-years of use. Other etiological factors include inhalation of biomass fuel smoke, environmental pollutants, occupational dust and chemicals, , and rare genetic conditions like (AAT) deficiency, which affects 1-2% of patients and leads to early-onset disease. Pathophysiologically, these exposures trigger an inflammatory response and protease-antiprotease imbalance, destroying alveolar walls and reducing the lung's , which exacerbates airflow limitation. Risk factors are amplified in individuals over 40, with higher among smokers (14%) compared to nonsmokers (3%). Symptoms of emphysema often develop gradually and include chronic (dyspnea), especially during physical activity, chronic with or without production, wheezing, chest tightness, and . In advanced stages, patients may exhibit , use of accessory respiratory muscles, , and signs of such as a barrel-shaped chest. Complications can be severe, encompassing , cor pulmonale (right-sided ), bullae formation, spontaneous (collapsed ), increased risk, and associated anxiety or depression. Diagnosis relies on clinical history, , and confirmatory showing a post-bronchodilator forced expiratory volume in one second (FEV1) to forced (FVC) ratio below 0.70, with severity staged from mild (FEV1 ≥80% predicted) to very severe (<30%). Additional tests may include chest X-rays or CT scans to visualize hyperinflation and bullae, arterial blood gas analysis for oxygenation levels, and AAT screening in younger patients or those without smoking history. Treatment emphasizes smoking cessation as the cornerstone intervention to halt progression, alongside bronchodilators (e.g., beta-2 agonists and anticholinergics), inhaled corticosteroids for exacerbations, pulmonary rehabilitation, oxygen therapy for hypoxemia (PaO2 <55 mmHg), and surgical options like lung volume reduction or transplantation in select severe cases. Preventive measures include vaccinations against influenza and pneumococcus, avoidance of pollutants, and early intervention for at-risk populations.

Overview and Epidemiology

Definition and Characteristics

Emphysema is a pathological condition of the lung characterized by the permanent, abnormal enlargement of airspaces distal to the terminal bronchioles, accompanied by destruction of their walls and without obvious fibrosis. This destruction leads to the coalescence of alveoli into larger, irregular airspaces, reducing the overall surface area available for gas exchange. The core features of emphysema include lung hyperinflation due to air trapping, loss of elastic recoil in the lung tissue, and progressive airflow obstruction during exhalation. These changes result from the degradation of alveolar walls, which normally provide structural support and elasticity to the lungs. Emphysema constitutes a primary pathological component of , contributing to the overall respiratory impairment in affected individuals. Emphysema primarily involves the acinus, the functional unit of the lung that encompasses the respiratory bronchioles, alveolar ducts, and alveoli. Damage within this structure disrupts the normal architecture, leading to inefficient ventilation and impaired oxygen diffusion. In distinction from chronic bronchitis, the other major form of COPD, emphysema does not feature prominent airway inflammation or mucus hypersecretion but instead emphasizes irreversible parenchymal destruction.

Prevalence and Distribution

Specific global prevalence estimates for emphysema are limited and often reported within the context of , of which emphysema is a major component; recent data indicate affects over 213 million people worldwide as of 2021, with age-standardized prevalence of about 2,700 per 100,000. Rates are significantly higher among smokers. In the , a general population cohort of adults aged 45-84, 5.4% had emphysema-like lung changes on exceeding the upper limit of normal. In the United States, over 3 million individuals live with emphysema as of recent estimates, with prevalence increasing with age. Annual incidence rates for emphysema are approximately 1-2% in high-risk groups such as long-term smokers over 40, though specific data are limited and often derived from COPD studies where emphysema is a predominant phenotype. Incidence is rising in developing countries, particularly due to increased exposure to biomass fuel smoke in household settings, which contributes to non-smoking-related cases. The condition predominantly affects individuals over 50 years, with historical disparities showing higher rates in males due to greater smoking prevalence, but rates are equalizing as female smoking patterns decline and male rates fall. In some regions, urban populations experience higher prevalence compared to rural ones, linked to air pollution and occupational exposures. Geographically, prevalence is higher in Europe and North America, reflecting historical high smoking rates. Cases are emerging in Asia alongside rising tobacco use, while in low- and middle-income countries, nearly 90% of related deaths under age 70 occur due to combined tobacco and indoor air pollution risks. Trends indicate a decline in high-income countries following smoking bans and tobacco control since 2000, with reductions observed in places like Sweden.

Pathophysiology

Mechanisms of Tissue Destruction

Emphysema arises from a complex interplay of cellular and biochemical processes that culminate in the irreversible destruction of alveolar walls. Central to this pathogenesis is the disruption of lung structural homeostasis, where inflammatory, proteolytic, oxidative, and apoptotic mechanisms overwhelm repair pathways, leading to airspace enlargement. These processes are primarily triggered by chronic insults such as , which activates resident immune cells and recruits additional inflammatory mediators to the lung parenchyma. A fundamental mechanism involves the protease-antiprotease imbalance, where proteolytic enzymes degrade the extracellular matrix (ECM) of the alveoli. Neutrophil elastase, released by activated neutrophils, plays a pivotal role by cleaving elastin and other ECM components, while matrix metalloproteinases (MMPs), particularly MMP-9 and MMP-12 from macrophages, further amplify tissue breakdown. This excess proteolysis overwhelms the inhibitory capacity of alpha-1 antitrypsin (A1AT), the primary serine protease inhibitor, which is inactivated by oxidative stress or reduced in concentration during inflammation. In severe cases, genetic A1AT deficiency exacerbates this imbalance, but it occurs broadly in smokers through functional impairment. Oxidative stress contributes significantly by generating reactive oxygen species (ROS) that directly damage lung tissue and perpetuate destructive cycles. Cigarette smoke delivers a massive oxidant burden—approximately 10^15 free radicals per puff—while activated inflammatory cells produce additional ROS, such as superoxide anions and hydrogen peroxide. These ROS inactivate antiproteases like , enhance protease activity, and induce mitochondrial dysfunction, leading to lipid peroxidation and DNA damage in alveolar cells. The resulting oxidative environment amplifies inflammation and impairs cellular repair, fostering progressive alveolar destruction. Inflammation pathways drive the recruitment and activation of immune cells that sustain tissue damage. Neutrophils and macrophages accumulate in the alveolar walls, drawn by chemokines such as (CXCL8) and leukotriene B4, leading to a 5- to 10-fold increase in their numbers compared to healthy lungs. These cells release pro-inflammatory cytokines, including and IL-8, which not only recruit more leukocytes but also stimulate the production of proteases and ROS. Macrophages, in particular, localize to sites of alveolar destruction, secreting that degrade elastin and collagen, while neutrophils contribute elastase-mediated injury, creating a self-reinforcing inflammatory milieu. Apoptosis of alveolar cells represents a critical downstream event in emphysema pathogenesis, where programmed cell death outpaces proliferation, resulting in net loss of septal structures. Type II pneumocytes, responsible for surfactant production and alveolar repair, undergo apoptosis via intrinsic pathways triggered by neutrophil elastase, which activates caspase-9 through reduced AKT phosphorylation, and by ROS-induced p53 activation leading to Bax translocation. Endothelial cells similarly succumb, with decreased VEGF signaling disrupting the PI3K/Akt anti-apoptotic pathway and increasing caspase activity. This dual apoptosis of epithelial and endothelial cells erodes alveolar integrity, enlarging airspaces without effective replacement. An imbalance in repair mechanisms further exacerbates destruction by hindering alveolar regeneration. Defective vascular endothelial growth factor (VEGF) signaling, marked by reduced VEGF and VEGFR2 expression in emphysematous lungs, impairs endothelial survival and vascular maintenance, promoting apoptosis and capillary rarefaction. Concurrently, diminished anti-apoptotic factors, such as those modulated by A1AT, fail to counteract caspase-3 activation, while cellular senescence limits proliferative capacity. This repair deficit transforms transient injury into permanent structural loss, underscoring the homeostatic failure in emphysema.

Structural and Functional Changes

Emphysema is characterized by the progressive destruction of alveolar septa, leading to the enlargement of airspaces distal to the terminal without accompanying fibrosis. This destruction results in a loss of the alveolar walls that normally support the pulmonary capillary bed, reducing the surface area available for gas exchange and contributing to ventilation-perfusion (V/Q) mismatch. These structural alterations promote lung hyperinflation, marked by an increase in residual volume (RV) and total lung capacity (TLC), often exceeding 120-130% of predicted values, due to air trapping from narrowed and collapsible small airways. The diaphragm becomes flattened as a result of this overexpansion, impairing its contractile efficiency and contributing to respiratory muscle dysfunction. Functionally, the loss of elastic fibers diminishes lung recoil pressure, exacerbating air trapping and leading to dynamic hyperinflation, particularly during physical exertion when expiratory time is limited. The impaired gas exchange in emphysema primarily manifests as hypoxemia, driven by V/Q mismatch where destroyed alveolar regions receive ventilation but inadequate perfusion, or vice versa, with high V/Q areas predominating in emphysematous lungs. In advanced stages, this can progress to hypercapnia as overall ventilatory capacity declines and alveolar hypoventilation worsens. Pulmonary function tests reflect these changes, with a reduced FEV1/FVC ratio below 70% indicating airflow obstruction, and a decreased diffusing capacity for carbon monoxide (DLCO) due to the diminished alveolar-capillary interface.

Causes and Risk Factors

Tobacco Smoking

Tobacco smoking is the predominant modifiable risk factor for emphysema, accounting for the majority of cases through chronic exposure to inhaled irritants that progressively destroy alveolar structures. Cigarette smoke consists of an aerosol containing over 7,000 chemical compounds, including tar, nicotine, carbon monoxide, and numerous others such as acrolein, formaldehyde, and benzene, many of which are highly reactive and contribute to alveolar wall damage by disrupting cellular repair and promoting fibrosis. These components, particularly the tar phase particulates and gas-phase oxidants, deposit in the lungs and initiate direct toxicity to epithelial cells, leading to impaired gas exchange and structural remodeling characteristic of emphysema. The pathogenic mechanisms involve cigarette smoke particles triggering an intense inflammatory response in the lung parenchyma, where alveolar macrophages and recruited neutrophils release reactive oxygen species (ROS) that overwhelm antioxidant defenses, causing oxidative stress and lipid peroxidation of alveolar membranes. This oxidative burden further amplifies inflammation by activating transcription factors like , which upregulate pro-inflammatory cytokines (e.g., TNF-α, IL-8) and stimulate the release of proteases such as neutrophil elastase and matrix metalloproteinases (MMPs) from inflammatory cells. The resulting protease-antiprotease imbalance degrades elastin fibers in the alveolar walls, leading to airspace enlargement and loss of elastic recoil, hallmarks of emphysematous tissue destruction. The risk of developing emphysema exhibits a clear dose-response relationship with cumulative tobacco exposure, measured in pack-years (one pack-year equaling 20 cigarettes per day for one year), with heavier smokers facing exponentially higher odds. For instance, in a study of South Korean adults, women with 20 or more pack-years of smoking history had an odds ratio of approximately 3.9 for , of which emphysema is a key component, compared to never-smokers. Even secondhand smoke exposure elevates risk, with meta-analyses indicating an odds ratio of about 2.25 for in never-smokers exposed to environmental tobacco smoke, particularly through chronic inhalation of similar toxicants at lower concentrations. Electronic cigarettes (e-cigarettes) and vaping products, which deliver nicotine and other aerosols, represent an emerging risk factor related to tobacco use. A 2025 meta-analysis found that current e-cigarette users had 1.48 times higher odds (95% CI: 1.36–1.61) of COPD compared to non-users, potentially due to similar mechanisms of oxidative stress and inflammation from inhaled particulates and flavoring chemicals, though long-term data specific to emphysema remain limited. The post-World War II surge in cigarette consumption, which peaked in the United States during the 1960s with adult prevalence exceeding 40%, precipitated a marked rise in emphysema incidence and mortality through the 1970s and 1980s as the 20- to 30-year latency period for disease manifestation elapsed. This temporal pattern reflected broader global trends, where increased smoking among men and later women amplified the population-level burden of smoking-attributable emphysema. Smoking cessation confers substantial benefits by attenuating the accelerated loss of lung function, as evidenced by reduced rates of forced expiratory volume in one second (FEV1) decline post-quitting. In the Lung Health Study, sustained quitters experienced an annual FEV1 decline of approximately 50 mL/year, compared to 80 mL/year among continuing smokers, highlighting how cessation halts further inflammatory progression and preserves residual lung capacity.

Genetic Factors

Alpha-1 antitrypsin deficiency (A1ATD) represents the most well-established genetic risk factor for emphysema, arising from mutations in the SERPINA1 gene on chromosome 14, which encodes the alpha-1 antitrypsin (AAT) protein, a key serine protease inhibitor. This condition follows an autosomal codominant inheritance pattern, where the severity of deficiency depends on the combination of alleles inherited from each parent. The PI*ZZ genotype, resulting from two deficient Z alleles, leads to profound AAT deficiency (typically less than 15% of normal levels) and predisposes individuals to early-onset panlobular emphysema, often manifesting in the third or fourth decade of life, particularly in the lower lobes of the lungs. A1ATD accounts for approximately 1-3% of severe chronic obstructive pulmonary disease (COPD) cases, including emphysema, in populations of European descent. The PIZ allele frequency is estimated at 1-2% among individuals of European ancestry, though the homozygous PIZZ genotype is rarer, affecting about 1 in 2,500 to 5,000 such individuals. In the pathogenesis of emphysema associated with A1ATD, reduced circulating AAT levels fail to adequately inhibit neutrophil elastase released during inflammation, resulting in unopposed proteolytic activity that progressively destroys alveolar walls and lung parenchyma. This protease-antiprotease imbalance is exacerbated in A1ATD, contributing to the characteristic tissue destruction observed in affected lungs. Beyond SERPINA1, variants in other genes have been implicated in modulating emphysema susceptibility, often through interactions with environmental factors like smoking. Polymorphisms in the matrix metalloproteinase 9 (MMP9) gene, which encodes an enzyme involved in extracellular matrix degradation, have been associated with increased risk of emphysema and COPD progression in certain populations. Similarly, single nucleotide polymorphisms in the tumor necrosis factor (TNF) gene, particularly those promoting elevated inflammatory cytokine production, may heighten susceptibility to lung tissue damage in emphysema. Research into polygenic risk scores, which aggregate the effects of multiple genetic variants across the genome, is emerging as a tool to predict emphysema and COPD liability, identifying individuals at higher risk even in the absence of severe monogenic deficiencies like A1ATD. Screening for A1ATD is recommended for all patients diagnosed with COPD or emphysema, with particular emphasis on those presenting with early-onset disease (before age 45), nonsmokers, or individuals with a family history of lung disease. Genotyping or phenotyping via blood tests can confirm A1ATD, enabling targeted monitoring and intervention to mitigate progression.

Environmental and Occupational Exposures

Environmental and occupational exposures to airborne irritants represent significant non-tobacco risk factors for emphysema, particularly through chronic inflammation and oxidative stress in the lung parenchyma. Long-term exposure to fine particulate matter () has been associated with increased risk of chronic obstructive pulmonary disease (), including emphysema, by promoting alveolar destruction and reduced lung function, especially in non-smokers. Ozone exposure exacerbates this risk, with studies showing combined effects of ambient ozone and household air pollution contributing to onset in young adults. Biomass fuel smoke from indoor cooking, prevalent in low- and middle-income countries, elevates levels up to 100 times above safe thresholds, leading to a 2.8- to 3-fold higher odds of among exposed women and children in poorly ventilated homes. Secondhand smoke and cooking fumes in low-income settings further compound indoor air pollution risks, accelerating emphysematous changes through persistent irritant inhalation. Occupational hazards, particularly in mining and welding, involve inhalation of inorganic dusts that directly contribute to emphysematous lung damage. Coal dust exposure in mining is linked to , which often features centrilobular emphysema alongside fibrosis, with odds ratios exceeding 3 for prolonged exposure. Silica dust, common in mining and construction, induces similar destructive changes, while cadmium fumes from welding and battery production activate matrix metalloproteinases and inflammation, independently causing emphysema even in never-smokers. These exposures heighten the risk of emphysema with impaired diffusing capacity, with odds ratios up to 3.79 in susceptible individuals. Joint statements from the American Thoracic Society (ATS) and European Respiratory Society (ERS) estimate that occupational exposures account for approximately 14% of cases overall and up to 31% among never-smokers, with higher attributable risks (10-20%) in dusty trades like mining and manufacturing. Professions such as coal miners, welders, and construction workers show prevalence ratios of 1.7 or greater for after 10 years of exposure. These risks often synergize with tobacco smoking, amplifying disease progression. Geographically, industrial regions with heavy mining activity exhibit elevated emphysema prevalence; in Central Appalachia, COPD affects 19.6% of adults aged 40 and older—over three times the U.S. national average—driven by coal and silica dust from thin-seam mining operations.

Other Etiologies

Other etiologies of emphysema are uncommon and collectively account for less than 5% of cases, predominantly affecting non-smokers. Infections contribute to emphysema through mechanisms such as immune dysregulation or scarring. infection is associated with an increased risk of emphysema independent of smoking, driven by chronic immune activation, inflammation, and protease-antiprotease imbalance in the lungs. Similarly, prior can lead to secondary emphysema via extensive scarring and fibrosis that distorts lung architecture and promotes compensatory overinflation in adjacent areas. Autoimmune diseases, particularly connective tissue disorders, can induce paracicatricial emphysema, where alveolar destruction occurs around fibrotic scars. Rheumatoid arthritis is a notable example, often presenting with combined pulmonary fibrosis and emphysema (CPFE), characterized by upper-lobe emphysema and lower-lobe fibrosis due to chronic inflammation and autoantibody-mediated tissue damage. Iatrogenic causes include certain medical interventions and drug abuse practices. Radiation therapy to the thorax may rarely result in bullous or localized emphysematous changes as a late complication of radiation-induced lung injury, though fibrosis is more typical. Intravenous abuse of drugs like methylphenidate (Ritalin), which contains talc as a filler, leads to "Ritalin lung"—a form of panlobular emphysema caused by talc microemboli that incite granulomatous inflammation and progressive alveolar destruction. Relatedly, intravenous talc from other crushed medications can produce similar talc granulomatosis and secondary emphysema through vascular occlusion and foreign body reactions. Congenital anomalies represent another rare etiology, with congenital lobar emphysema arising from intrinsic bronchial cartilage deficiencies or extrinsic bronchial compression, leading to air trapping and hyperinflation of affected lobes during early development.

Clinical Presentation

Respiratory Symptoms

The primary respiratory symptom of emphysema is dyspnea, or shortness of breath, which typically begins insidiously during physical exertion and progresses over years to occur even at rest as lung damage advances. This symptom arises from airflow obstruction due to alveolar destruction and air trapping, increasing the work of breathing and limiting daily activities. Dyspnea severity is often assessed using the modified Medical Research Council (mMRC) scale, a five-point tool ranging from 0 (no breathlessness except with strenuous exercise) to 4 (too breathless to leave the house or breathless when dressing), which helps correlate symptoms with disease impact. In pure emphysema, cough is usually minimal and dry, with little sputum production, distinguishing it from chronic bronchitis where productive cough predominates; however, some patients may experience occasional coughing as the disease overlaps with other COPD components. Wheezing, a high-pitched whistling sound during exhalation, and chest tightness often accompany these symptoms, resulting from hyperinflation and trapped air in the damaged , which narrows airways and causes a sensation of pressure. Acute exacerbations represent sudden worsenings of these respiratory symptoms, frequently triggered by respiratory infections such as viral or bacterial pathogens, leading to intensified dyspnea, increased cough, and greater respiratory effort that may require medical intervention. The overall symptom timeline in emphysema follows a gradual progression aligned with Global Initiative for Chronic Obstructive Lung Disease (GOLD) stages, where early stages () feature mild exertional dyspnea and minimal cough, advancing in later stages () to severe, persistent symptoms at rest with frequent exacerbations, reflecting worsening airflow limitation.

Systemic Manifestations

Emphysema, as a primary component of , extends its pathological effects beyond the pulmonary system, leading to significant multi-organ involvement. Systemic manifestations arise from chronic hypoxemia, persistent inflammation, and the resulting physiological adaptations, contributing to increased morbidity and reduced quality of life. One prominent cardiovascular complication is , characterized by right ventricular hypertrophy and dilation secondary to pulmonary hypertension induced by alveolar destruction and vascular remodeling in emphysema. This right heart strain impairs cardiac output and exacerbates hypoxemia, occurring in up to 30-50% of advanced cases and serving as a marker of disease severity. In emphysema patients, is often subtle ("cor pulmonale parvus") but correlates with reduced exercise tolerance and higher mortality risk. Cachexia manifests as involuntary weight loss, skeletal muscle wasting, and fat depletion, driven by systemic inflammation involving elevated cytokines such as tumor necrosis factor-alpha and interleukin-6. This condition affects 20-40% of emphysema patients, particularly those with severe airflow obstruction, and is linked to accelerated protein catabolism and impaired nutrient utilization. Muscle wasting further diminishes peripheral strength and endurance, compounding respiratory disability. Osteoporosis, marked by reduced bone mineral density and increased fracture risk, is prevalent in 20-40% of advanced emphysema cases due to factors including chronic hypoxia, corticosteroid therapy, and physical immobility from dyspnea. Hypoxia disrupts osteoblast function and promotes osteoclast activity, while long-term glucocorticoids inhibit bone formation. Vertebral fractures, in particular, can worsen posture and respiratory mechanics, creating a vicious cycle. Chronic fatigue and depression are common neuropsychiatric effects, stemming from persistent hypoxemia and diminished physical activity levels. Fatigue, reported by over 70% of patients, arises from reduced oxygen delivery to muscles and central nervous system fatigue, severely limiting daily functioning. Depression affects approximately 40% of individuals with emphysema, exacerbated by hypoxemia-induced neurochemical imbalances and social isolation from activity restriction, and is associated with poorer adherence to therapy. Emphysema also heightens the risk of comorbidities such as cardiovascular disease (CVD) and type 2 diabetes, with patients facing 2-3 times the incidence compared to age-matched controls. Systemic inflammation and oxidative stress in emphysema promote atherosclerosis and endothelial dysfunction, elevating CVD events like myocardial infarction. Similarly, insulin resistance is amplified by chronic inflammation and adipokine dysregulation, increasing diabetes prevalence by 1.5-2 fold. These comorbidities synergistically worsen prognosis, underscoring the need for integrated management.

Diagnosis

Clinical Assessment

The clinical assessment of emphysema begins with a detailed history-taking to identify risk factors and symptom progression. Clinicians inquire about smoking history, as 80-90% of cases are associated with tobacco use, typically manifesting after at least 20 pack-years of exposure. Occupational and environmental exposures, such as dust, chemicals, or biomass fuels, are also explored, particularly in non-smokers or those from developing regions. A family history of (A1ATD) is critical, affecting 1-2% of patients and often leading to earlier disease onset. The history further documents symptom onset, including chronic dyspnea and cough that initially occur with exertion but progress to rest, guiding the evaluation of disease severity. Physical examination reveals signs of hyperinflation and airflow limitation in advanced emphysema. Inspection may show a barrel chest due to increased anterior-posterior diameter from lung hyperinflation. Auscultation often detects prolonged expiratory phase and decreased breath sounds bilaterally, reflecting airway obstruction and reduced air movement. In severe cases, use of accessory respiratory muscles, such as the sternocleidomastoid, indicates increased work of breathing. Severity grading incorporates the BODE index, a multidimensional tool that predicts mortality and prognosis more effectively than FEV1 alone in emphysema and chronic obstructive pulmonary disease (COPD). It assesses four components: body mass index (B), degree of airflow obstruction via FEV1 (O), dyspnea using the modified Medical Research Council scale (D), and exercise capacity measured by the 6-minute walk distance (E). Higher scores indicate greater severity and poorer outcomes. Red flags during assessment prompt further investigation to rule out alternative or complicating conditions. Early onset of symptoms, particularly before age 45 in non-smokers, suggests genetic causes like . Hemoptysis, though uncommon in uncomplicated emphysema, indicates potential alternative diagnoses such as infection, bronchiectasis, or malignancy, necessitating urgent referral. Patient-reported outcomes enhance the assessment by capturing health-related quality of life impacts. The St. George's Respiratory Questionnaire (SGRQ) is a validated tool for emphysema and COPD, measuring symptoms, activity limitations, and psychosocial effects through three domains, with total scores ranging from 0 to 100 (higher indicating worse quality of life). Respiratory symptoms like dyspnea and cough, as reported by patients, inform the interpretation of these scores during clinical evaluation.

Imaging Techniques

Chest X-ray remains the initial imaging modality for evaluating suspected emphysema, commonly revealing hyperinflation with flattened diaphragms, increased retrosternal airspace, and barrel-shaped chest configuration, along with potential bullae or increased lucency. However, its sensitivity is limited, particularly for mild or early disease, with reported detection rates as low as 40% when compared to computed tomography (CT) findings. Computed tomography (CT), especially high-resolution CT (HRCT), is the gold standard for confirming emphysema diagnosis and assessing its extent, as it directly visualizes parenchymal destruction through low-attenuation areas (typically defined by Hounsfield units below -950 HU) that correspond to alveolar wall loss. HRCT enhances diagnostic utility by providing detailed cross-sectional images that distinguish emphysema patterns, such as centrilobular involvement predominantly in upper lobes versus panlobular distribution in lower lobes. Quantitative assessment on CT, including the Goddard score—a semi-quantitative visual method scoring emphysema involvement (0-4) across six lung zones for a total of 0-24—correlates strongly with automated densitometric measures and aids in evaluating disease severity and heterogeneity. Emerging imaging modalities like magnetic resonance imaging (MRI) offer complementary functional insights without ionizing radiation; for instance, oxygen-enhanced MRI and dynamic contrast-enhanced perfusion MRI detect ventilation-perfusion (V/Q) mismatches in emphysematous regions, supporting evaluation of gas exchange abnormalities. Quantitative CT techniques further enable longitudinal tracking of emphysema progression by measuring changes in low-attenuation volume over time, which is valuable for monitoring therapeutic responses. Radiation exposure from CT scans poses considerations for repeated imaging in emphysema patients, but low-dose protocols (e.g., 20-30 mAs) maintain diagnostic accuracy for emphysema quantification while reducing effective dose to levels comparable to chest X-rays, minimizing long-term risks.

Pulmonary Function Testing

Pulmonary function testing (PFT) is essential for confirming the diagnosis of emphysema, assessing its severity, and monitoring disease progression by quantifying airflow limitation, hyperinflation, and gas exchange impairment. These tests reveal characteristic patterns of obstruction and alveolar destruction, distinguishing emphysema from other respiratory conditions. In emphysema, PFTs typically demonstrate irreversible airflow obstruction, air trapping, and reduced diffusing capacity, with results interpreted against predicted values based on age, sex, height, and ethnicity. Spirometry is the cornerstone of PFT in emphysema, measuring forced vital capacity (FVC) and forced expiratory volume in 1 second (FEV1), with the FEV1/FVC serving as the primary diagnostic criterion. A post-bronchodilator FEV1/FVC below 0.70 indicates airflow obstruction consistent with emphysema or (COPD). FEV1 is often reduced, with severity graded as mild (≥80% predicted), moderate (50% to <80% predicted), severe (30% to <50% predicted), or very severe (<30% predicted). Post-bronchodilator testing is crucial to exclude reversible components like , as emphysema shows limited reversibility. Lung volume measurements, obtained via body plethysmography or gas dilution techniques, detect and hallmarks of emphysema. Total lung capacity () is frequently increased (>120% predicted) due to loss of , while residual volume (RV) rises markedly from premature airway closure. The RV/ ratio, normally <35%, exceeds this threshold (often >60% in severe cases) and signifies , correlating with dyspnea and . These abnormalities reflect emphysematous destruction of alveolar walls, leading to dynamic during expiration. Diffusing capacity for carbon monoxide (DLCO) quantifies efficiency and is markedly reduced in emphysema due to alveolar-capillary destruction and loss of vascular bed. DLCO values below 75% predicted, even with normal , support an emphysema , as it isolates parenchymal damage from pure airway obstruction. This test is particularly useful in early or mild cases where may be less sensitive. gas (ABG) analysis complements PFT by directly measuring of oxygen (PaO2) and (PaCO2) to evaluate abnormalities, particularly (PaO2 <55 mmHg) or in advanced emphysema, guiding decisions for . Exercise testing, such as the 6-minute walk test (6MWT), evaluates functional capacity and oxygen desaturation in emphysema patients. During the 6MWT, a drop in (SpO2) of ≥4%—often to ≤88%—is common, especially in moderate to severe disease, reflecting ventilation-perfusion mismatch and under stress. This desaturation occurs rapidly (within the first minute) and predicts mortality risk, guiding decisions. Serial PFTs enable monitoring of emphysema progression, with annual FEV1 decline averaging 50-100 mL/year in moderate to severe cases, accelerated by ongoing or exacerbations. This rate varies by , with emphysematous COPD showing steeper declines (e.g., 13 mL/year greater than non-emphysematous forms), emphasizing the need for annual to track response to interventions like or .

Differential Diagnosis

Emphysema, a form of (COPD), often presents with progressive dyspnea and airflow limitation, necessitating careful differentiation from other respiratory and cardiac conditions to guide appropriate management. Symptoms such as exertional can overlap with various disorders, but distinct clinical features, pulmonary function tests (PFTs), imaging, and therapeutic responses aid in distinguishing emphysema. Asthma is a primary differential, characterized by reversible airflow obstruction in response to bronchodilators or allergens, unlike the largely irreversible limitation seen in emphysema. Patients with often have a history of , episodic wheezing triggered by irritants or exercise, nocturnal symptoms, and elevated counts or IgE levels, which are less common in emphysema. PFTs in asthma typically show significant improvement in forced expiratory volume in one second (FEV1) post-bronchodilator, whereas emphysema demonstrates minimal reversibility. Chronic bronchitis, another COPD phenotype, must be differentiated based on predominant productive cough with sputum hypersecretion for at least three months in two consecutive years, often preceding airflow obstruction, in contrast to the dyspnea-dominant presentation of emphysema with less sputum production. While both share smoking history as a risk factor, chronic bronchitis features less hyperinflation on imaging and may show normal spirometry in early stages, whereas emphysema exhibits marked air trapping and reduced diffusing capacity. Interstitial lung disease (ILD) presents with restrictive physiology and on (HRCT), differing from the obstructive pattern and bullous lucencies characteristic of emphysema. Dyspnea in ILD is often accompanied by dry cough and fine inspiratory , with PFTs revealing reduced total lung capacity and no significant response, unlike the and airflow limitation in emphysema. Heart failure mimics emphysema through exertional dyspnea and fatigue, but features , paroxysmal nocturnal dyspnea, , and signs of fluid overload, which are absent in isolated emphysema. is key to identifying cardiac dysfunction such as reduced or elevated pulmonary pressures in , while emphysema lacks these findings and shows on chest imaging. In cases of early-onset emphysema, particularly in nonsmokers or those under 45 years, (AAT) deficiency should be excluded through serum AAT level measurement and , as it causes a genetic form of panlobular emphysema distinct from smoking-related centrilobular disease. Low AAT levels confirm the deficiency, which predisposes to basilar-predominant emphysema and may require augmentation therapy, unlike typical emphysema management. Key discriminators include PFT patterns—obstructive with low FEV1/forced vital capacity ratio and reduced diffusing capacity in emphysema versus restrictive or reversible changes in alternatives—HRCT findings of emphysema-specific lucencies and versus or elsewhere, and poor response to bronchodilators or lack of improvement with diuretics in emphysema compared to or .

Classification and Types

Centrilobular Emphysema

Centrilobular emphysema, also known as proximal acinar emphysema, is the most common subtype of pulmonary emphysema, characterized by the abnormal permanent enlargement of airspaces in the central portion of the secondary pulmonary lobule, accompanied by destruction of their walls without obvious fibrosis. It predominantly affects the proximal respiratory bronchioles within the acinus, with a characteristic upper lobe predominance, particularly in the superior segments of the lower lobes and the inner zones of the lung. This form accounts for the majority of emphysema cases related to cigarette smoking, with autopsy studies indicating its presence in up to 50% of adult smokers, and it represents the predominant pattern in 70-90% of smoking-associated chronic obstructive pulmonary disease (COPD) cases. The pathogenesis of centrilobular emphysema is closely linked to long-term cigarette smoking, which induces chronic inflammation in the proximal acinus by recruiting inflammatory cells such as macrophages, neutrophils, and T lymphocytes. These cells release proteolytic enzymes, including neutrophil elastase and matrix metalloproteinases, which degrade elastin and other extracellular matrix components in the respiratory bronchioles, leading to airspace enlargement and loss of elastic recoil. Smoking also promotes oxidative stress and mucus hypersecretion, exacerbating the protease-antiprotease imbalance and focal destruction that begins centrally and spares the distal alveoli and alveolar ducts initially. In advanced stages, the destruction can progress to involve more of the acinus, potentially resembling panlobular patterns with confluent emphysematous spaces. On (HRCT), centrilobular emphysema appears as small, round, centrilobular lucencies (typically 1-10 mm) with ill-defined borders in early stages, centered around the centrilobular arteries and evenly distributed without extensive lung hyperinflation. These lucencies reflect the focal destruction, initially sparing the distal alveolar regions, which helps distinguish it from other subtypes. Clinically, the upper lobe predominance of centrilobular emphysema correlates with relatively preserved in early disease due to the heterogeneous distribution and maintenance of some alveolar-capillary units in affected areas, resulting in less severe compared to more uniform destructive patterns. However, as the disease advances, airflow limitation worsens due to reduced and airway collapse during expiration.

Panlobular Emphysema

Panlobular emphysema, also known as panacinar emphysema, is a subtype of pulmonary emphysema defined by the uniform enlargement and destruction of airspaces throughout the entire , extending from the respiratory bronchioles to the alveoli within the secondary pulmonary lobule. This results in a diffuse, homogeneous pattern of tissue loss without the proximal-distal seen in other forms. Unlike centrilobular emphysema, which predominantly affects the upper lobes in smokers, panlobular emphysema shows a basal predominance, with more severe changes typically observed in the lower lung fields. The condition is strongly associated with (A1ATD), a that impairs the protective function of against proteolytic enzymes, leading to unchecked lung tissue degradation. It is also linked to Swyer-James syndrome, a post-infectious that can cause unilateral hyperlucency and lobular involvement. In pathogenesis, panlobular emphysema arises from widespread protease-antiprotease imbalance, often due to excess activity from inflammatory cells, resulting in even alveolar wall breakdown across the lobule without regional variation. On imaging, (HRCT) reveals diffuse low-attenuation regions encompassing the entire lobule, appearing more homogeneous and ill-defined compared to the patchy, centrilobular distribution. These changes may show polygonal borders in localized forms or blend into broader hazy opacities in diffuse cases, with reduced visibility of peripheral vessels as severity increases. Clinically, panlobular emphysema often manifests with an earlier onset and faster disease progression, particularly in non-smokers affected by hereditary factors such as A1ATD. Patients may experience greater dyspnea and reduced exercise capacity—such as a 6-minute walk distance at 73% of predicted value—independent of the degree of airflow obstruction, alongside and diminished .

Paraseptal Emphysema

Paraseptal emphysema, also known as distal acinar emphysema, is defined by the enlargement of airspaces in the distal portion of the , specifically adjacent to the pleura and interlobular septa. This subtype predominantly affects the peripheral regions of the lobule, involving the alveolar ducts and sacs near the lung surface. Unlike more central forms, it is confined to the margins of the secondary pulmonary lobule, sparing the central proximal acinar structures. The of paraseptal emphysema involves localized destruction of alveolar walls in the distal , often linked to inflammatory processes from smoke exposure that target the peripheral airways and adjacent vasculature. This destruction leads to enlargement without significant involvement of bronchioles, potentially contributing to disruptions in pulmonary or pleural capillaries. While the exact mechanisms remain under study, the pattern suggests a gradient of injury from the pleura inward, distinguishing it from other emphysematous subtypes. Prevalence of paraseptal emphysema varies by population, occurring in approximately 3% of community-dwelling individuals but rising to 15% among smokers with (COPD), with a higher incidence in men. It is commonly identified in current or former smokers, though it frequently remains and is discovered incidentally on . This subtype often coexists with other forms of emphysema but can present independently. On imaging, paraseptal emphysema manifests as subpleural regions of low attenuation or well-defined cystic spaces on (HRCT), typically along the fissures and peripheral lung zones. These lucencies are most prominent in the upper lobes and dorsal surfaces, aiding differentiation from centrilobular patterns. The presence of extensive paraseptal changes increases the risk of secondary due to potential rupture of weakened peripheral structures. Clinically, paraseptal emphysema is usually associated with minimal or no respiratory symptoms, particularly when mild and isolated, allowing affected individuals to remain unaware of its presence. Symptoms may only emerge if complications arise, such as rupture leading to , which can occur spontaneously in younger adults despite limited overall function impairment. Routine monitoring is recommended for those with identified changes to assess progression.

Bullous Emphysema

Bullous emphysema represents a distinct subtype of emphysema characterized by the formation of bullae, defined as sharply demarcated, air-filled spaces greater than 1 cm in diameter within the lung parenchyma, resulting from the irreversible destruction and enlargement of alveolar spaces. These bullae typically arise from paraseptal emphysema, where damage is concentrated in the peripheral acini near the pleura. Approximately 80% of patients with bullae also exhibit underlying emphysema, often linked to (COPD). The involves the coalescence of adjacent alveoli destroyed by chronic inflammation, commonly triggered by cigarette smoke or other irritants, leading to the loss of alveolar walls and . This process forms thin-walled cystic structures that impair and contribute to airflow limitation. Bullae predominantly develop in the apical regions of the upper lobes, where paraseptal changes are most pronounced, though they can occur subpleurally or more diffusely in advanced cases. On imaging, bullous emphysema manifests as large, lucent areas on computed tomography () scans, often compressing and displacing adjacent normal tissue, which helps differentiate it from other cystic lesions. Chest radiographs may show radiolucent e outlined by thin white lines, but provides superior sensitivity for detection and characterization. Clinically, patients experience progressive dyspnea, primarily due to the mechanical compression of functional lung parenchyma by expanding bullae; a significant complication is the risk of bulla rupture, which can lead to spontaneous .

Paracicatricial Emphysema

Paracicatricial emphysema, also known as irregular or scar emphysema, is a subtype of emphysema characterized by localized destruction of alveolar walls adjacent to areas of or scarring. This form is distinct from other emphysema types due to its direct association with fibrotic processes, resulting in airspace enlargement limited to the vicinity of scars. It commonly occurs around fibrotic scars caused by prior infections such as , , or granulomatous diseases like . The scarring leads to architectural distortion in the surrounding lung parenchyma, where normal lung tissue is pulled and stretched by the contracting fibrous tissue. The involves mechanical traction exerted by the fibrotic , which dilates and enlarges adjacent without the typical proteolytic destruction seen in smoking-related emphysema. This traction-based mechanism causes irregular dilation of alveoli and respiratory bronchioles near the scar, often resulting in mild to moderate airspace enlargement that is not extensive. Paracicatricial emphysema is frequently observed in advanced lung diseases involving , including cases with overlap between (COPD) and lung abnormalities, though specific data are limited. It is noted in a subset of patients with mixed obstructive and restrictive lung involvement. On imaging, (HRCT) reveals characteristic irregular lucencies or focal areas of low attenuation adjacent to fibrotic bands, scars, or areas of architectural distortion, often appearing as enlarged airspaces or small bullae abutting the scarred regions. These findings help differentiate it from more diffuse emphysema patterns. Clinically, paracicatricial emphysema is often unless extensive, with symptoms primarily attributable to the underlying condition. It contributes to a mixed pattern on pulmonary function tests, combining obstructive defects from destruction with restrictive impairment due to , such as reduced alongside airflow limitation.

Deficiency-Related Emphysema

Alpha-1 antitrypsin deficiency (AATD) is a that predisposes individuals to early-onset emphysema, particularly in those with severe deficiency such as the PI*ZZ genotype. This form of emphysema is characterized by a distinct where reduced levels of the protective protease inhibitor lead to unchecked activity in the lungs, resulting in tissue destruction. Unlike smoking-related emphysema, which often affects upper lobes, AATD-related emphysema exhibits a unique distribution and progression pattern influenced by the underlying genetic defect. The emphysema in AATD is predominantly panlobular with a basal predominance, involving uniform destruction across the and primarily affecting the lower lobes of the lungs. This distribution arises from the gravitational settling of pollutants and the relatively lower AAT concentrations in the lower lung zones, exacerbating proteolytic damage. typically reveals diffuse panlobular emphysema in the lung bases, often progressing to severe airflow obstruction by . Screening for AATD is recommended in patients with early-onset emphysema, especially those with lower lobe involvement, to identify this treatable genetic cause. Onset of emphysema in AATD typically occurs earlier in smokers, around age 30-40 years, compared to non-smokers, where symptoms may emerge between 45-50 years. accelerates lung function decline by further impairing AAT function and increasing , leading to dyspnea and reduced exercise tolerance at a younger age. In non-smokers, environmental factors like exposure in childhood can also hasten symptom onset, though the progression is generally slower. Liver involvement complicates approximately 10-15% of AATD cases in adults, where misfolded AAT proteins polymerize and accumulate in hepatocytes, leading to . These polymers trigger stress and , distinct from the pathology, and may manifest as elevated liver enzymes or even without prior childhood . The PI*ZZ confers the highest risk for this gain-of-function liver toxicity. Diagnosis of AATD-related emphysema involves measuring AAT levels, with concentrations below 80 mg/dL indicating potential deficiency and prompting further evaluation. Confirmatory identifies the PI*ZZ variant as the most severe form, associated with AAT levels of 20-35 mg/dL, while phenotyping distinguishes deficient alleles like and . Early through targeted screening in at-risk populations, such as those with unexplained early emphysema, enables for both pulmonary and hepatic complications. Without intervention, in AATD-related emphysema features accelerated function decline, with forced expiratory in one second (FEV1) decreasing at 80-100 mL per year in , compared to slower rates in non-smokers. This rapid progression correlates with baseline FEV1 levels and history, increasing risks of and mortality by age 50-60 in severe cases. Longitudinal studies highlight the variability, but overall survival is reduced without addressing modifiable factors like exposure.

HIV-Associated Emphysema

HIV-associated emphysema refers to the accelerated development of emphysema in individuals living with , characterized by a higher and more severe manifestations compared to HIV-uninfected populations. Studies have reported emphysema rates of 15-33% among people with HIV (PWH), particularly those who , compared to 2-15% in matched controls without HIV. This condition predominantly manifests as centrilobular emphysema, often linked to smoking history, though HIV infection independently elevates risk even in non-smokers, with rates up to 18% in lifelong non-smoking PWH versus 4% in controls. The pathogenesis involves HIV-induced immune dysregulation, particularly profound depletion of + T-cells in the lungs, which leads to unchecked chronic and protease-antiprotease imbalance. This depletion, driven by activation-induced , impairs the lung's ability to regulate inflammatory responses to insults like cigarette smoke, resulting in alveolar destruction. Even with antiretroviral therapy (), persistent low CD4/CD8 ratios correlate with increased emphysema risk, highlighting ongoing immune impairment despite viral suppression. Emphysema in PWH often presents earlier and more severely than in the general , with accelerated progression independent of in some cases and synergistic worsening in smokers. On computed () imaging, it shows diffuse involvement across lung zones, with a higher propensity for bullae formation and greater overall emphysema severity compared to HIV-uninfected individuals. Clinically, PWH with emphysema exhibit worse (DLCO) and reduced exercise tolerance, contributing to increased respiratory symptoms and mortality risk.

Ritalin Lung

Ritalin lung refers to a rare form of iatrogenic panlobular emphysema resulting from the intravenous injection of crushed (Ritalin) tablets, a practice historically associated with . This condition arises when insoluble excipients, particularly (magnesium silicate), present in the tablets are emulsified and injected, leading to pulmonary complications. Unlike smoking-related emphysema, it occurs in young individuals without significant exposure, often presenting as severe, precocious . The mechanism involves emboli lodging in the pulmonary arterioles and capillaries, provoking a reaction that forms granulomas. These granulomas cause vascular , ischemic of surrounding tissue, and progressive destruction of alveolar walls, culminating in panlobular emphysema. Although the precise remains incompletely understood, the absence of in affected patients underscores the role of these rather than genetic factors. This process differs from other talc-related diseases, where larger particles may produce more prominent nodular changes. The emphysema in Ritalin lung is typically panlobular or focal and predominantly affects the lower zones (basal-predominant ), though bilateral involvement is common. It was most prevalent among intravenous drug users in the 1970s and 1980s, when diversion for peaked, but cases remain rare today due to changes in formulation and awareness. Small and clinical series document only a handful of patients, highlighting its uncommon nature even within abuse cohorts. On imaging, computed tomography () reveals a micronodular pattern in early stages due to talc granulomas, which may evolve into diffuse emphysematous lucencies with vascular and loss of . Radiographic findings mimic those of emphysema but occur in a younger demographic. Clinically, patients—often young non-smokers—experience progressive dyspnea, severe airflow obstruction, and reduced exercise tolerance, with the damage frequently irreversible and leading to in advanced cases.

Combined Pulmonary Fibrosis and Emphysema (CPFE)

Combined pulmonary fibrosis and emphysema (CPFE) is a distinct defined by the coexistence of emphysema predominantly in the upper zones and in the lower zones, typically identified on (HRCT) scans. This entity is characterized by subnormal with relatively preserved lung volumes, severe impairment in as evidenced by reduced of the for (DLCO), a high prevalence of , and an overall poor . It most commonly affects older male smokers, distinguishing it from isolated emphysema or (IPF). The of CPFE involves shared risk factors and mechanisms, with cigarette serving as the primary common trigger in the vast majority of cases. likely promotes both emphysematous destruction through protease-antiprotease imbalance and fibrotic remodeling via and . Emerging evidence points to potential genetic links, including telomere dysfunction (e.g., mutations in TERT) and polymorphisms in the MUC5B promoter gene, which may predispose individuals to concurrent airspace enlargement and interstitial scarring. Autoimmune phenomena and gastroesophageal reflux have also been implicated as contributing factors in subsets of patients. Prevalence estimates for CPFE vary by population and diagnostic criteria, ranging from 1-5% in (COPD) cohorts to 8-61% among patients with IPF. It is more frequent in males over 60 years of age, with studies reporting up to 85% of cases occurring in current or former smokers. The syndrome accounts for approximately 5-10% of idiopathic diffuse parenchymal lung diseases in epidemiological records. On HRCT imaging, CPFE typically manifests as centrilobular or paraseptal emphysema in the upper lobes, often with bullae, alongside basal predominant featuring (in about 95% of cases), reticular opacities (87%), and traction (69%). This biphasic distribution contrasts with the more uniform patterns seen in pure emphysema or . Clinically, patients with CPFE present with progressive exertional dyspnea, , and bilateral basal , alongside finger clubbing in about 43% of cases. Despite near-normal , DLCO is markedly reduced (often <40% predicted), reflecting combined ventilatory and diffusive defects. Severe pulmonary hypertension develops in 47-90% of patients at diagnosis, contributing to right heart strain and exercise intolerance. Prognosis is dismal, with median survival of 3-6 years and 5-year survival rates of 35-55%; the presence of pulmonary hypertension halves 5-year survival to around 25%.

Swyer-James Syndrome

Swyer-James syndrome, also known as Macleod syndrome, is a rare variant of characterized by unilateral pulmonary hyperlucency resulting from post-infectious lung damage during childhood. This condition involves acquired hypoplasia of one lung or a lobe, leading to reduced vascularity and alveolar hyperdistention, distinguishing it as a post-infectious form of obstructive lung disease rather than the typical smoking-related . First described in case reports in the early 1950s, it represents a sequela of that impairs normal lung growth and function. The etiology of Swyer-James syndrome traces back to severe respiratory infections in infancy or early childhood, most commonly viral bronchiolitis obliterans caused by agents such as adenovirus, respiratory syncytial virus (RSV), measles, or influenza. These infections trigger obliterative bronchiolitis, which damages the small airways and pulmonary vasculature, resulting in arrested alveolar development and hypoplasia of the affected lung. The inflammatory process leads to fibrosis and reduced perfusion, creating a hypoplastic lung with compensatory overinflation of the contralateral lung over time. Key radiographic features include unilateral hyperlucency on chest X-ray due to decreased vascular markings and air trapping, alongside a small pulmonary artery and reduced lung volume on the affected side. Mosaic perfusion is evident, reflecting heterogeneous ventilation and perfusion mismatches, often with bronchiectasis or bullae formation in advanced cases. These changes create a characteristic "small lung" appearance, with the affected hemithorax potentially appearing smaller than the opposite side. Swyer-James syndrome is exceedingly rare, with a prevalence estimated at approximately 0.01% based on large-scale chest radiograph surveys, accounting for less than 1% of all emphysema cases. It is often underdiagnosed due to its subtle presentation and overlap with other unilateral lung pathologies. Computed tomography (CT) imaging is the gold standard for diagnosis, revealing reduced vascularity, air trapping on expiratory views, and mosaic attenuation patterns that confirm the obliterative changes. High-resolution CT may also show emphysema-like destruction, peripheral bronchiectasis, and oligemia (reduced blood flow) in the affected lung, aiding differentiation from congenital or neoplastic causes. Clinically, many individuals with Swyer-James syndrome remain asymptomatic into adulthood, with the condition discovered incidentally on imaging. Symptomatic cases may present with exertional dyspnea, recurrent respiratory infections, or cough, particularly if there is bilateral involvement or significant compensatory hyperinflation of the unaffected lung. Pulmonary function tests typically demonstrate obstructive patterns with reduced diffusion capacity on the affected side.

Congenital Lobar Emphysema

Congenital lobar emphysema (CLE) is a rare congenital anomaly of lung development characterized by progressive overdistension and hyperinflation of one or more pulmonary lobes, resulting from air trapping without parenchymal destruction. This condition arises during fetal lung maturation and typically manifests in the neonatal period, leading to potential respiratory compromise due to compression of adjacent lung tissue and mediastinal shift. Unlike acquired forms of emphysema, CLE stems from intrinsic developmental defects rather than environmental or inflammatory insults. The pathogenesis of CLE primarily involves abnormal bronchial cartilage development, such as dysplasia, hypoplasia, or deficiency, which weakens the airway walls and predisposes them to collapse during expiration. This dynamic airway obstruction traps air within the affected lobe, causing progressive hyperinflation that compresses surrounding normal lung parenchyma and can impair ventilation. In some cases, polyalveolar lobes with excessive alveoli may contribute to increased compliance and air retention, though the exact etiology remains idiopathic in most instances. The left upper lobe is the most frequently affected site, involved in approximately 43% to 45% of cases, followed by the right middle lobe (around 32%) and right upper lobe (about 21%); multilobar involvement is rare but possible. This distribution reflects the anatomical vulnerabilities in upper and middle lobe bronchi during embryogenesis. Clinical presentation often occurs in the first few months of life, with nearly half of cases symptomatic at birth and the remainder developing signs by six months; symptoms include progressive respiratory distress, wheezing, cyanosis, tachypnea, and feeding difficulties due to the hyperinflated lobe's mass effect. Diagnosis is primarily achieved through chest X-ray, which reveals lobar hyperlucency, mediastinal shift, and potential atelectasis of adjacent lobes, while computed tomography (CT) provides confirmatory detail on the extent of hyperinflation and rules out other malformations. Prenatal ultrasound may occasionally detect it as a cystic lesion. The incidence of CLE is estimated at 1 in 20,000 to 30,000 live births, representing about 10% to 15% of all congenital lung malformations, with a slight male predominance. It is more common in term infants and has no strong genetic associations identified to date. Management focuses on symptomatic relief, with conservative observation sufficient for asymptomatic or mildly affected infants, as many cases resolve spontaneously. However, for moderate to severe respiratory distress, surgical lobectomy of the affected lobe is the definitive treatment, offering excellent outcomes with low morbidity when performed early. Postoperative prognosis is generally favorable, with most children achieving normal lung function.

Focal Emphysema

Focal emphysema is characterized by small, localized areas of permanent airspace enlargement distal to the terminal bronchioles, accompanied by destruction of alveolar walls, but without the widespread involvement typical of advanced emphysematous diseases. This form represents mild, patchy emphysematous changes that do not substantially compromise global lung architecture or function. The term was originally introduced to describe a less severe variant of lung destruction with broader but limited distribution compared to diffuse forms. The primary causes of focal emphysema include age-related alterations known as senile emphysema, compensatory expansion following surgical resection such as , and initial inflammatory responses to smoking. Senile emphysema results from natural aging processes that lead to subtle acinar modifications and mild airspace dilation without significant wall destruction, often considered a physiological rather than pathological change. Compensatory emphysema develops when viable lung tissue hyperinflates to offset the loss of function in resected or atelectatic regions, as seen post-, restoring partial volume through expansion of the remaining parenchyma. Early cigarette smoking can induce focal centrilobular emphysema through localized inflammation and protease-antiprotease imbalance in the central lobular areas, representing an initial stage of smoke-related damage in asymptomatic individuals. These lesions are typically scattered diffusely across the lungs with only mild involvement, lacking confinement to specific lobes or zones. On computed tomography (CT) imaging, focal emphysema manifests as subtle focal lucencies or low-attenuation regions, often measuring up to 1 cm in diameter and surrounded by normal lung parenchyma, commonly identified incidentally during scans for unrelated issues. High-resolution CT is particularly sensitive for detecting these early, non-confluent changes, while conventional chest radiography may overlook them due to their limited extent. Clinically, focal emphysema is generally asymptomatic, with no associated respiratory symptoms such as dyspnea, cough, or sputum production, distinguishing it from symptomatic . It tends to progress very slowly or remain stable over time, rarely evolving into diffuse disease without additional risk factors, and thus seldom requires specific management beyond monitoring.

Complications

Respiratory Complications

Emphysema predisposes individuals to several lung-specific complications arising from alveolar destruction, airflow limitation, and impaired gas exchange. These include pneumothorax, recurrent infections, acute exacerbations, pulmonary hypertension, and respiratory failure, which can significantly worsen disease progression and quality of life. Pneumothorax occurs when subpleural bullae rupture, allowing air to escape into the pleural space and causing lung collapse. This complication is particularly life-threatening in severe emphysema due to preexisting lung damage, often requiring urgent intervention such as chest tube drainage. Patients with emphysema face an elevated risk of secondary spontaneous pneumothorax compared to those without underlying lung disease. Recurrent respiratory infections, such as bronchitis and pneumonia, are common due to impaired mucociliary clearance and mucus hypersecretion in damaged airways. These infections exacerbate inflammation and airflow obstruction, increasing susceptibility in patients with emphysema-dominant chronic obstructive pulmonary disease (COPD). Bacterial and viral pathogens colonize the lower airways more readily, leading to frequent episodes that prolong recovery and contribute to lung function decline. Acute exacerbations manifest as sudden worsening of dyspnea, cough, and sputum production, typically triggered by respiratory infections or environmental pollutants. In moderate emphysema, patients experience an average of 1-2 exacerbations per year, with frequency increasing alongside disease severity. These events accelerate emphysema progression by promoting further airway inflammation and alveolar damage. Pulmonary hypertension develops from chronic hypoxemia-induced vasoconstriction in pulmonary arteries, elevating vascular resistance and pressure. This hypoxic pulmonary vasoconstriction, a response to low oxygen levels in emphysematous lungs, leads to right ventricular strain and eventual cor pulmonale, characterized by right heart enlargement and failure. In advanced emphysema, this complication correlates with severe hypoxemia (PaO2 <59 mmHg) and worsens prognosis. Respiratory failure in emphysema initially presents as type 1 (hypoxemic), with inadequate oxygenation due to ventilation-perfusion mismatch and alveolar hypoventilation. As disease advances, it progresses to type 2 (hypercapnic) failure, involving CO2 retention from worsening airflow limitation and respiratory muscle fatigue. This sequence heightens the risk of acute decompensation during exacerbations, often necessitating mechanical ventilation.

Systemic Complications

Emphysema contributes to systemic complications through chronic hypoxia, systemic inflammation, and shared risk factors with other diseases, affecting multiple organ systems and increasing morbidity. These extrapulmonary effects arise primarily from the disease's impact on oxygen delivery and inflammatory cascades, leading to heightened vulnerability in non-respiratory tissues. is a prevalent comorbidity in emphysema patients, with a pooled global prevalence of approximately 38% based on bone mineral density assessments across multiple studies. Chronic hypoxia promotes bone resorption by activating hypoxia-inducible factor 1α (HIF-1α), which enhances osteoclast differentiation and impairs bone formation. This results in a 2- to 5-fold higher risk of osteoporosis compared to age-matched healthy individuals, alongside an elevated fracture risk, particularly vertebral fractures, due to reduced bone density and increased fall propensity. Cardiovascular complications are accelerated in emphysema due to systemic inflammation and oxidative stress, which promote endothelial dysfunction and atherosclerotic plaque formation. Patients face approximately a 2-fold increased odds of cardiovascular disease overall, including ischemic heart disease. Specifically, the risk of myocardial infarction is roughly doubled, independent of traditional risk factors like smoking, with exacerbations further heightening thrombotic tendencies. Cachexia and sarcopenia manifest as significant muscle wasting in emphysema, affecting 15% to 40% of patients and driven by cytokine-mediated catabolism. Elevated levels of proinflammatory cytokines such as (TNF-α) and (IL-6) activate pathways like and the ubiquitin-proteasome system, leading to selective type II fiber atrophy and reduced fat-free mass. This muscle loss exacerbates exercise intolerance and contributes to a negative protein turnover balance, often compounded by systemic inflammation referenced in broader pathophysiology discussions. Mental health issues, including anxiety and depression, show a comorbidity prevalence of around 40% in emphysema patients, stemming from the chronic burden of breathlessness and reduced quality of life. Anxiety affects up to 40% and depression up to 25%, with higher rates in severe cases, correlating with increased exacerbation frequency and poorer disease outcomes. Emphysema slightly elevates lung cancer risk beyond smoking alone, primarily through shared etiological factors like chronic inflammation and genetic susceptibilities. The presence of emphysema on CT imaging is associated with a 2- to 4-fold increased odds of lung cancer, particularly in centrilobular phenotypes, highlighting the interplay of destructive lung remodeling and oncogenic processes.

Management and Treatment

Lifestyle and Supportive Measures

Smoking cessation is the cornerstone of managing emphysema, as continued tobacco use accelerates lung function decline and increases mortality risk. Interventions such as nicotine replacement therapy, behavioral counseling, and pharmacologically supported programs are recommended to facilitate quitting, with evidence showing that cessation reduces total mortality by approximately 30-50% in patients with chronic obstructive pulmonary disease (COPD), of which emphysema is a primary component. Early cessation after diagnosis yields the greatest benefits, slowing disease progression and decreasing the frequency of exacerbations. Pulmonary rehabilitation programs, encompassing supervised exercise training, nutritional counseling, and education on self-management, significantly enhance quality of life and physical capacity in emphysema patients. These multidisciplinary approaches improve exercise tolerance, as measured by the 6-minute walk distance (6MWD), by approximately 50 meters on average, enabling better daily functioning and reduced dyspnea. Participation in such programs, typically lasting 6-12 weeks, also fosters long-term adherence to healthy behaviors, mitigating the sedentary tendencies associated with advanced emphysema. Nutritional strategies address the cachexia and weight loss prevalent in emphysema, where hyperinflation and increased energy expenditure contribute to malnutrition. High-calorie diets supplemented with adequate protein (aiming for 1.2-1.5 g/kg body weight daily) help counteract muscle wasting and support respiratory muscle function, with oral nutritional supplements shown to promote weight gain and improve exercise performance in undernourished patients. Tailored intake, emphasizing energy-dense foods and possibly omega-3 fatty acids, is particularly beneficial for those with low body mass index. Annual influenza vaccination and pneumococcal immunization with PCV20 or PCV21 (as per current CDC/ACIP guidelines for adults 50 years and older) are essential preventive measures to avert infections that trigger exacerbations in emphysema patients. These vaccines reduce the incidence of acute exacerbations by up to 50-70% and lower hospitalization rates for respiratory complications. Routine administration aligns with global health recommendations for high-risk groups. Long-term oxygen therapy (LTOT) is indicated for emphysema patients with severe hypoxemia, defined as a partial pressure of arterial oxygen (PaO2) below 55 mmHg or oxygen saturation ≤88% at rest. Delivered continuously (at least 15 hours daily), LTOT extends survival by 1-2 years compared to nocturnal use alone, as demonstrated in landmark trials like the , which reported a 45% reduction in mortality risk with continuous therapy. This intervention also alleviates symptoms and improves sleep quality, but requires careful monitoring to ensure adherence and avoid complications like oxygen toxicity.

Pharmacotherapy

Pharmacotherapy for emphysema primarily targets symptom relief, improvement in lung function, and prevention of exacerbations, as there is no cure for the underlying alveolar destruction. Treatments follow guidelines for chronic obstructive pulmonary disease (COPD), of which emphysema is a key component, emphasizing stepwise escalation based on symptom severity, exacerbation history, and lung function metrics like forced expiratory volume in one second (FEV1). Bronchodilators form the cornerstone of therapy, relaxing airway smooth muscle to alleviate dyspnea and enhance airflow. Long-acting beta-2 agonists (LABAs), such as and , improve FEV1 by approximately 100-150 mL and reduce breathlessness, with evidence from randomized controlled trials showing sustained benefits over 12-24 weeks compared to placebo. Long-acting muscarinic antagonists (LAMAs), including and , provide similar FEV1 gains of 120-200 mL and are particularly effective in reducing exacerbation frequency by up to 20-25% versus short-acting options, due to their longer duration of action. Dual LABA/LAMA combinations, such as , yield additive FEV1 improvements of 150-250 mL and superior symptom control over monotherapy, making them first-line for moderate-to-severe emphysema with persistent symptoms. Inhaled corticosteroids (ICS) are reserved for patients with frequent exacerbations (two or more per year) or those with an asthma-COPD overlap, often combined with LABAs to mitigate risks like pneumonia. Fluticasone propionate, for instance, in fixed-dose combinations with salmeterol, reduces moderate-to-severe exacerbation rates by about 25% compared to bronchodilator monotherapy, with benefits most pronounced in patients with blood eosinophil counts above 300 cells/μL. This effect stems from anti-inflammatory actions that stabilize airways, though ICS do not alter long-term FEV1 decline and are not recommended for monotherapy in pure emphysema phenotypes; de-escalation is advised based on eosinophil counts or adverse events per 2025 guidelines. Phosphodiesterase-4 (PDE4) inhibitors like roflumilast are indicated for severe emphysema (FEV1 <50% predicted) with chronic bronchitis and a history of exacerbations despite optimal bronchodilator therapy. Administered orally once daily, roflumilast reduces moderate-to-severe exacerbations by 15-20% and provides modest FEV1 improvements of 50-100 mL when added to existing regimens, targeting inflammation in the lower airways. Its use is limited by side effects such as weight loss and gastrointestinal upset, restricting it to select high-risk patients. For emphysema due to alpha-1 antitrypsin (A1AT) deficiency, augmentation therapy involves weekly intravenous infusions of purified A1AT (e.g., 60 mg/kg) to raise serum levels and protect lung tissue from proteolytic damage. Meta-analyses of randomized trials demonstrate that this slows FEV1 decline by approximately 20-23% (or 10-15 mL/year) compared to non-augmented controls, particularly in patients with moderate airflow obstruction (FEV1 30-65% predicted). Therapy is lifelong and monitored via A1AT levels, but it does not reverse existing emphysema. Mucolytics, such as N-acetylcysteine (NAC), play a limited adjunctive role in emphysema management, primarily for patients with viscous sputum and frequent exacerbations not controlled by bronchodilators. High-dose oral NAC (600 mg twice daily) modestly reduces exacerbation frequency by 20-25% and improves health status in non-ICS users, possibly through antioxidant effects that thin mucus and reduce oxidative stress. Evidence is inconsistent across populations, and routine use is not endorsed outside chronic bronchitis phenotypes. Biologics targeting type 2 inflammation are recommended in the 2025 GOLD guidelines for patients with eosinophilic COPD and frequent exacerbations despite optimized bronchodilators. Dupilumab, a monoclonal antibody blocking IL-4 and IL-13, reduces moderate-to-severe exacerbations by about 30% and improves lung function in phase III trials (BOREAS and NOTUS), with approvals in the US (2024), EU, Japan (2025), Canada (2025), and other regions for adults with inadequately controlled COPD and type 2 inflammation (e.g., blood eosinophils ≥300 cells/μL). Mepolizumab, an anti-IL-5 monoclonal antibody, is approved in the US (May 2025) as add-on maintenance for eosinophilic COPD, reducing exacerbations by 20-25% in trials.

Surgical Options

Surgical options are considered for patients with advanced emphysema who remain symptomatic despite optimal medical therapy and pulmonary rehabilitation. These procedures aim to improve lung function, exercise capacity, and quality of life by addressing hyperinflation and irreversible tissue damage. The primary surgical interventions include lung volume reduction surgery (LVRS), bullectomy, and lung transplantation, each with specific indications, eligibility criteria, and associated risks. Lung volume reduction surgery (LVRS) involves the resection of 20-30% of the most damaged lung tissue, typically from the upper lobes, to allow healthier lung regions to expand and function more effectively. The National Emphysema Treatment Trial (NETT) demonstrated that LVRS provides a survival benefit in patients with upper-lobe predominant emphysema and low exercise capacity, with a 5-year survival rate of 70% compared to 60% with medical therapy alone. Eligibility for LVRS requires severe emphysema confirmed by pulmonary function tests (e.g., FEV1 20-35% predicted), heterogeneous distribution on CT imaging, completion of a pulmonary rehabilitation program, and abstinence from smoking for at least 4 months. Contraindications include severe comorbidities such as unstable coronary artery disease, severe pulmonary hypertension, or FEV1 below 20% predicted without upper-lobe predominance. Complications occur in up to 90% of cases, with prolonged air leaks (lasting >7 days) in 10-20% and of 5-10%, particularly higher (up to 16%) in high-risk groups like those with low exercise capacity and diffuse emphysema. Bullectomy is indicated for the removal of giant bullae—large air-filled sacs occupying more than 30% of the hemithorax—that compress adjacent functional lung tissue and contribute to dyspnea. This procedure, often performed via video-assisted thoracoscopic surgery, can improve FEV1 by 15-20% postoperatively by allowing re-expansion of compressed parenchyma. Candidates for bullectomy typically have a single dominant bulla with preserved underlying lung function (FEV1 >40% predicted) and no diffuse severe emphysema. Severe comorbidities or multiple small bullae are contraindications. Complications include prolonged air leaks in 10-20% of cases and perioperative mortality of approximately 5%, with overall functional improvements sustained for at least 1-3 years in most patients. Lung transplantation is reserved for end-stage emphysema patients with FEV1 <20% predicted, severe , or recurrent exacerbations despite maximal therapy. Single or bilateral replaces diseased lungs with donor organs, offering the most definitive treatment for eligible candidates who are non-smokers, have completed , and lack major comorbidities like active or severe frailty. The 5-year is 50-60%, with median survival around 5 years, though bilateral procedures may yield slightly better long-term outcomes (up to 66% at 5 years). Post-transplant complications include primary graft dysfunction (up to 20%), chronic rejection (bronchiolitis obliterans syndrome in 50% by 5 years), and of 5-10%, emphasizing the need for lifelong and close .

Bronchoscopic Interventions

Bronchoscopic interventions represent minimally invasive alternatives to surgical volume reduction for with severe emphysema, targeting hyperinflated regions to improve respiratory mechanics and symptoms. These procedures, performed via flexible under or general , aim to reduce volume by blocking to damaged areas or inducing targeted contraction, thereby alleviating —a key pathophysiological feature where residual volume exceeds 175% of predicted. Approved options include endobronchial valves, lung volume reduction coils, and vapor , each suited to specific emphysema patterns and profiles. Endobronchial valves, such as the valves, are one-way devices deployed in the airways of hyperinflated lobes to achieve by preventing air entry while allowing exhalation. In the LIBERATE trial, a multicenter randomized controlled study of 190 patients with heterogeneous emphysema, Zephyr valve treatment resulted in a mean FEV1 improvement of approximately 10-15% at 12 months compared to standard care, alongside gains in exercise tolerance and . These valves are particularly effective in patients with complete interlobar integrity, confirmed by or collateral ventilation testing, to ensure targeted lobe isolation. Lung volume reduction coils, made from nitinol—a —are bronchoscopically placed in subsegmental airways of heterogeneous emphysema regions to mechanically compress damaged , reducing and enhancing . Clinical trials, including the RENEW study involving 316 patients, demonstrated modest with FEV1 increases of 7-11% and residual volume reductions of 0.31-0.71 L at 12 months, particularly benefiting those with upper-lobe predominant . Coils are advantageous for patients ineligible for valves due to collateral ventilation but require multiple deployments (typically 10-12 per lobe) across sessions to achieve volume reduction. Thermal vapor ablation, using the InterVapor system, involves delivering heated water vapor (at 75°C) to selected emphysematous segments, provoking an inflammatory response that leads to absorption atelectasis, , and subsequent volume reduction. In a multicenter of 44 patients with upper-lobe heterogeneous emphysema, this technique yielded a 48% lobar volume decrease (approximately 716 mL) at 6 months, with FEV1 improvements of about 141 mL and enhanced 6-minute walk distance, effects sustained to 12 months in responders. The procedure targets lobes with high emphysema destruction scores and is limited to 1-2 segments per session to manage post-treatment inflammation. Eligibility for these interventions emphasizes heterogeneous emphysema distribution, confirmed by high-resolution , and significant with residual volume greater than 175% predicted, alongside FEV1 between 15-45% predicted and adequate exercise capacity. Patients must lack active , severe comorbidities, or diffuse disease, with pre-procedure assessments including to identify target lobes. These criteria ensure benefits outweigh risks in carefully selected individuals with post-bronchodilator FEV1 responsiveness limited by trapped air. Overall outcomes include reduced COPD exacerbations—observed in up to 40% fewer events annually with valves in real-world data—and improved dyspnea scores, though benefits vary by and adherence to . Complications, while generally manageable on an outpatient basis, encompass (5-10% incidence across methods, higher at 26% with valves requiring drainage in most cases), transient exacerbations, and , with serious adverse events occurring in 20-30% within 30 days. Long-term follow-up from pivotal trials indicates sustained functional gains for 1-5 years in responders, positioning these interventions as bridges to or standalone therapy for non-surgical candidates.

Emerging Therapies

Emerging therapies for emphysema focus on regenerative and targeted biological approaches to address the underlying alveolar destruction and , particularly in patients with (A1AT) deficiency or advanced disease where standard treatments fall short. , particularly using mesenchymal stem cells (MSCs), aims to regenerate damaged alveoli through their immunomodulatory and reparative properties. Preclinical models have demonstrated that MSCs can reduce , promote tissue repair, and improve lung function in elastase-induced emphysema. Phase I and II clinical trials have shown MSCs to be generally safe, with some evidence of modest improvements in forced expiratory volume in one second (FEV1), such as a reported increase of approximately 100-150 mL in select cohorts of severe (COPD) patients with emphysematous features after intravenous or endobronchial administration. However, larger phase II studies, including those evaluating multiple doses over 52 weeks, have not consistently demonstrated significant FEV1 gains or sustained benefits, highlighting the need for optimized dosing and patient selection. Ongoing phase III trials, such as the RESPIRE protocol using adipose-derived MSCs, are assessing long-term efficacy in improving FEV1 and in moderate-to-severe emphysema. Anti-inflammatory biologics target specific cytokines to modulate protease-antiprotease imbalances implicated in emphysema progression. Inhibitors of interleukin-13 (IL-13), such as and tralokinumab, have been investigated for their in reducing hypersecretion and airway remodeling, with phase II trials in COPD showing potential reductions in rates among patients with elevated IL-13 levels. , a blocking the IL-4 and IL-13 shared receptor, has demonstrated significant benefits in phase III trials (BOREAS and NOTUS) for COPD patients with , including a 30% reduction in moderate-to-severe exacerbations and improved lung function. In contrast, (TNF) inhibitors like and have largely failed to show clinical efficacy in emphysema or COPD trials, with phase II and III studies reporting no significant impact on exacerbations or lung function despite preclinical of TNF's in inflammation; concerns, including increased risk, have limited further development. Itepekimab (anti-IL-33) in the AERIFY program showed mixed results, meeting the primary endpoint for in AERIFY-1 (27% at week 52 in former smokers with COPD) but not in AERIFY-2. The RESOLUTE trial for benralizumab (anti-IL-5R) did not meet its primary endpoint for in September 2025. Depemokimab (anti-IL-5) is under evaluation in ongoing phase III trials (e.g., ENDURA-2, initiated 2025) for ultra-long-acting effects on lung function in type 2-high COPD. Gene therapy represents a promising avenue for A1AT-deficient emphysema, where adeno-associated virus (AAV) vectors deliver functional A1AT genes to restore antiprotease levels and halt lung destruction. Early phase I/II trials using intramuscular or aerosolized AAV vectors, such as AAV1 and AAV2 serotypes, have achieved stable transgene expression with serum A1AT levels reaching 10-20% of normal for up to a year, alongside evidence of slowed emphysema progression on computed tomography. A phase I trial initiated in 2025 with AAV8-hAAT(AVL), an oxidation-resistant variant (NCT06996756), is evaluating safety and efficacy in adults with A1AT deficiency and emphysema, focusing on durable A1AT production without immune rejection. Challenges include vector immunogenicity and transient expression, but intrapleural delivery approaches in preclinical and early human studies show potential for higher lung-specific A1AT levels. Retinoids, such as all-trans (ATRA), seek to promote alveolar repair by activating retinoic acid receptors that regulate and remodeling. models of emphysema have shown ATRA to induce septal formation and reduce airspace enlargement. Early , including a phase II pilot study administering oral ATRA (1-2 mg/kg/day) for 12 weeks, reported tolerability but no significant radiographic or functional improvements in emphysema patients. The FORTE phase II similarly found no overall benefit in density or FEV1, leading to a failed phase III effort with ATRA; however, selective retinoid agonists like palovarotene and gamma-selective variants are under investigation in preclinical and early-phase studies as of 2025 to enhance specificity and avoid systemic . As of November 2025, the landscape for emphysema therapies includes phase III trials for biologics like depemokimab, with persistent challenges involving selecting appropriate endpoints beyond FEV1, such as imaging-based emphysema progression and patient-reported outcomes, to better capture disease modification in heterogeneous populations.

Prognosis and Prevention

Prognostic Factors

Prognostic factors in emphysema play a crucial role in predicting patient outcomes and guiding therapeutic decisions, with disease severity, comorbidities, phenotypic characteristics, and response to s serving as key determinants. Overall, the median survival after of emphysema ranges from 5 to 10 years, varying by stage and management, though this can be substantially extended through early . Disease severity, often assessed via forced expiratory volume in one second (FEV1), is a primary predictor of survival; patients with FEV1 less than 30% of predicted value experience approximately halved 5-year survival rates compared to those with milder obstruction, reflecting advanced airflow limitation and hyperinflation. The Global Initiative for Chronic Obstructive Lung Disease () staging system, which incorporates FEV1, further stratifies risk in emphysema as a COPD subtype. The 2025 report emphasizes cardiovascular comorbidities, including and , as significant modifiers of prognosis, increasing mortality risk in advanced emphysema. Comorbidities significantly influence , with the BODE index—a composite score integrating (BMI), degree of obstruction (FEV1), dyspnea (via modified Medical Research Council scale), and exercise capacity (6-minute walk test)—providing a robust predictive tool. A BODE score greater than 7 indicates poor , correlating with heightened mortality risk from or exacerbations, as validated in large cohorts where such scores predicted up to 80% mortality within 4 years. Emphysema also affects outcomes, with upper-lobe predominant centrilobular emphysema generally conferring a better than diffuse panlobular forms due to less extensive alveolar destruction and better preservation of lower lobe function. Panlobular emphysema, often linked to , is associated with more severe airflow obstruction, greater symptom burden, and reduced exercise capacity. Response to therapy, particularly lung volume reduction (LVRS), offers prognostic insight; patients with upper-lobe predominant emphysema and low baseline exercise capacity derive significant survival benefits post-LVRS, including reduced mortality and improved , as demonstrated in the National Emphysema Treatment Trial. Emerging biologic therapies, such as approved in 2025 for COPD phenotypes, may further improve prognosis by reducing exacerbation frequency and preserving function in responsive patients. Smoking cessation markedly improves prognosis in emphysema patients, potentially increasing survival by up to 50% compared to continued by slowing disease progression and reducing exacerbation frequency.

Prevention Strategies

initiatives targeting tobacco use have significantly contributed to the prevention of emphysema, a primary component of (COPD). Anti- campaigns and policies, including taxation, advertising bans, and smoke-free legislation, have led to substantial declines in prevalence, which in turn has reduced COPD incidence rates since 2000. For instance, population-based strategies have demonstrated the potential to lower overall COPD by addressing the leading modifiable . Occupational safety measures play a crucial role in preventing emphysema among workers exposed to respiratory irritants. Effective dust control through local exhaust ventilation systems and the use of (PPE), such as respirators, can minimize inhalation of harmful particles like silica or in industries including , , and manufacturing. Regulatory standards from agencies like the (OSHA) emphasize and appropriate PPE to reduce occupational contributions to COPD, which account for a notable population-attributable fraction of cases. Genetic screening for (A1AT) deficiency is recommended for individuals with a family history of early-onset emphysema or COPD, enabling early intervention to mitigate progression. Testing identifies those with low A1AT levels, a genetic present in about 1% of COPD cases, allowing for targeted avoidance of and environmental exposures. Clinical guidelines advocate familial screening to facilitate preventive measures, such as augmentation therapy in deficient individuals, which can preserve lung function when initiated early. Environmental regulations aimed at improving air quality are essential for emphysema prevention, particularly in reducing exposure to ambient pollutants and indoor smoke. Policies limiting and nitrogen oxides from industrial and vehicular sources have been shown to lower COPD risks and support overall health. Programs replacing traditional stoves with cleaner alternatives, such as chimney-equipped or efficient models, have demonstrated substantial reductions in COPD in high-exposure populations, like those in rural areas reliant on solid fuels. The 2025 GOLD report highlights the growing impact of , including more frequent extreme weather events, on COPD exacerbations, recommending preventive strategies such as enhanced disaster preparedness and air quality monitoring to mitigate risks for vulnerable populations. Early detection through screening is a key strategy for at-risk populations, such as smokers over 40 years old, to identify preclinical airflow obstruction before symptomatic emphysema develops. Routine can detect reduced forced expiratory volume in one second (FEV1) in individuals, enabling and other interventions to halt progression. Studies support targeted screening in this demographic, where undiagnosed obstruction prevalence can reach 20-25%, allowing for timely preventive actions.

History

Early Descriptions

The earliest recorded observations of respiratory conditions resembling emphysema date back to ancient times, where symptoms of breathlessness were noted without specific anatomical correlation to lung pathology. Around 450 BCE, Hippocrates, often regarded as the father of medicine, described a condition termed "asthma," derived from the Greek word for panting or labored breathing, characterized by episodes of severe dyspnea and wheezing triggered by environmental factors such as dust or cold air. This portrayal emphasized breathlessness as a primary symptom but did not yet distinguish it from other forms of respiratory distress, framing it more as a symptomatic state than a distinct disease entity. The term "emphysema" itself emerged in the , marking the first explicit reference to overinflation as a pathological finding. In 1679, Théophile Bonet, in his work Sepulchretum, provided the inaugural description of "voluminous s" observed during autopsies, coining the term "emphysema" from the Greek en (in) and phýsa (to inflate or blow), to denote the abnormal inflation and enlargement of tissue. Bonet's observations were based on post-mortem examinations and highlighted the s' failure to collapse properly, though clinical symptoms were not yet systematically linked to this finding. By the early , more detailed clinical and pathological characterizations solidified emphysema as a recognizable entity, distinct from other respiratory ailments like . In 1821, French physician René Laënnec, inventor of the , detailed emphysema in his Traité de l'auscultation médiate, describing autopsied as pale, mottled, hyperinflated, and containing bullae—large air-filled spaces—while noting their poor collapsibility and association with dyspnea, particularly in older men who were often smokers. Laënnec observed that this condition manifested as chronic, worsening in middle-aged and elderly males, with post-mortem examinations revealing marked lung overdistension, and he explicitly differentiated emphysema from , viewing it as a separate pathological process involving alveolar destruction rather than inflammatory mucus production. These insights, drawn from clinical and correlations, established emphysema as a disorder of structure, predating modern understandings of .

Key Milestones in Understanding

In the , epidemiological research established a strong causal link between cigarette smoking and emphysema, building on earlier observations of chronic respiratory disease in smokers. Pioneering work by and , through their prospective cohort studies initiated in the early , demonstrated that heavy smoking significantly increased mortality from diseases, including emphysema as a component of chronic and . Concurrently, Noel C. Oswald and colleagues provided a detailed pathological description of centriacinar emphysema in 1953, identifying it as a predominant form in smokers characterized by dilation of respiratory bronchioles in the central lobule, which advanced understanding of the disease's morphological subtypes. The 1960s marked pivotal advances in the genetic and biochemical underpinnings of emphysema. In 1963, Carl-Bertil Laurell discovered (A1ATD) while analyzing serum protein patterns, revealing low levels of this protease inhibitor in patients with unexplained emphysema, thus linking genetic factors to early-onset disease. In 1964, proposed the protease-antiprotease imbalance theory, experimentally inducing emphysema-like changes in animal lungs using , an enzyme that degrades , thereby suggesting that unchecked proteolytic activity from neutrophil elastase could destroy alveolar walls in susceptible individuals. During the 1970s, diagnostic and therapeutic foundations for emphysema evolved with the introduction of computed tomography (CT) imaging and early explorations of lung volume reduction. The first clinical CT scanners, developed by in 1971, enabled non-invasive visualization of lung parenchyma by the mid-1970s, allowing detection of emphysematous changes like bullae and that were previously obscured on plain radiographs. Precursors to the National Emphysema Treatment Trial (NETT) emerged through initial studies on surgical interventions, including reports of unilateral lung volume reduction procedures that improved ventilation-perfusion matching in select patients with severe emphysema, setting the stage for randomized evaluations. The solidified evidence-based treatments and refined etiological models. The NETT, a multicenter published in 2003, enrolled 1,218 patients with severe emphysema and found that lung volume reduction surgery (LVRS) improved exercise capacity and compared to medical therapy alone, particularly in those with upper-lobe predominant and low baseline exercise tolerance, though it increased short-term mortality risk in high-risk subgroups. This trial's results led to coverage for LVRS in qualified patients. Additionally, studies in the confirmed the protease-antiprotease imbalance as a core mechanism, with biochemical analyses showing elevated activity and reduced inhibitors like A1AT in emphysematous s of smokers, validating Gross's earlier hypothesis through human tissue and biomarker data. In the 2010s and 2020s, genomic and minimally invasive approaches advanced emphysema research. Genome-wide association studies (GWAS) identified novel susceptibility loci, such as variants near HHIP and IREB2 genes associated with emphysema severity and distribution on CT scans, enhancing risk prediction beyond A1ATD and informing personalized medicine. The U.S. Food and Drug Administration approved the Zephyr endobronchial valve in 2018 for bronchoscopic lung volume reduction in severe emphysema patients with no collateral ventilation, based on the LIBERATE trial demonstrating significant improvements in lung function and six-minute walk distance. Ongoing stem cell trials, including phase I/II studies using mesenchymal stem cells to modulate inflammation and promote alveolar repair, show preliminary safety and modest efficacy in reducing emphysema progression, with larger trials in progress to assess long-term outcomes. As of 2024, an early clinical trial in China involving pulmonary stem cell transplants in 20 COPD patients suggested improvements in lung function, highlighting continued progress in regenerative approaches.

References

  1. [1]
    Emphysema - Symptoms and causes - Mayo Clinic
    Nov 19, 2024 · Emphysema is a long-term lung condition that causes shortness of breath. Over time, the condition damages the thin walls of the air sacs in the lungs called ...
  2. [2]
    Emphysema - StatPearls - NCBI Bookshelf
    Mar 28, 2025 · This condition destroys alveolar walls, air trapping, and impaired gas exchange, resulting in symptoms like shortness of breath, chronic cough, ...Etiology · History and Physical · Treatment / Management · Differential Diagnosis
  3. [3]
    Emphysema | American Lung Association
    Emphysema is a progressive lung disease that causes shortness of breath. It is also referred to as chronic obstructive lung disease (COPD).
  4. [4]
    Pathogenesis of hyperinflation in chronic obstructive pulmonary ...
    In a significant proportion of patients with COPD, reduced lung elastic recoil combined with expiratory flow limitation eventually leads to lung hyperinflation ...
  5. [5]
    What Is COPD? - NHLBI - NIH
    Nov 8, 2024 · COPD is a lung disease that makes it hard to breathe. It includes emphysema and chronic bronchitis. COPD is a major cause of disability and ...
  6. [6]
    Emphysema: Video, Causes, & Meaning - Osmosis
    Emphysema means “inflate or swell”, which makes sense because in the lungs of people with emphysema, the alveolar air sacs, which are the thin walled air spaces ...
  7. [7]
    COPD / Emphysema | UCSF Pulmonary, Critical Care, Allergy and ...
    Chronic Bronchitis is a clinical diagnosis, based on a history of cough and sputum production. Emphysema involves destruction of lung tissue, and can be ...
  8. [8]
    COPD Trends Brief - Prevalence | American Lung Association
    Emphysema. Prevalence - 2018; Adult Prevalence, 1999-2018. Prevalence - 2018. In 2018, 2.0 million adults, or 1.6% of those ages 18 or older, had emphysema.
  9. [9]
    Associations between emphysema-like lung on CT and ... - PubMed
    Emphysema on CT is associated with accelerated lung function decline in heavy smokers and patients with COPD; however, in the general population, it is not ...
  10. [10]
    Epidemiology of COPD | European Respiratory Society
    Prevalence of COPD varies according to country, age and sex. This disease is also associated with significant comorbidities.
  11. [11]
    Chronic obstructive pulmonary disease (COPD)
    Nov 6, 2024 · Chronic obstructive pulmonary disease (COPD) is the fourth leading cause of death worldwide, causing 3.5 million deaths in 2021, approximately 5 ...Symptoms · Causes · Treatment
  12. [12]
    International variation in the prevalence of COPD (the BOLD Study)
    Sep 1, 2007 · Findings: The prevalence of stage II or higher COPD was 10.1% (SE 4.8) overall, 11.8% (7.9) for men, and 8.5% (5.8) for women. The ORs for 10- ...
  13. [13]
    Decreased COPD prevalence in Sweden after decades of decrease ...
    Oct 28, 2020 · The prevalence of COPD has decreased in Sweden, and the prevalence of moderate to severe COPD was particularly low.Missing: declining | Show results with:declining
  14. [14]
    Cellular and Molecular Mechanisms of Alveolar Destruction in ...
    Emphysema consists of a unique pattern of alveolar destruction, resulting in marked airspace enlargement with reduction of alveolar capillary exchange area.
  15. [15]
    Role of Proteases in Chronic Obstructive Pulmonary Disease - PMC
    Aug 8, 2017 · This review is specifically focused on the role of proteases and their imbalance in COPD. There are three classes (serine, mettalo, and cysteine) of proteases ...
  16. [16]
    Oxidative Stress in Chronic Obstructive Pulmonary Disease - PMC
    May 13, 2022 · Oxidative stress is a major driving mechanism of COPD through the induction of chronic inflammation, induction of cellular senescence and impaired autophagy.
  17. [17]
    https://pmc.ncbi.nlm.nih.gov/articles/PMC9138026/
  18. [18]
    Inflammation and Immune Response in COPD: Where Do We Stand?
    Increasing evidence indicates that chronic inflammatory and immune responses play key roles in the development and progression of COPD.
  19. [19]
    https://pmc.ncbi.nlm.nih.gov/articles/PMC3728539/
  20. [20]
    Alveolar epithelial and endothelial cell apoptosis in emphysema - NIH
    In this review, we will focus on the recent developments made on the involvement of apoptosis in emphysema and on the possible molecular mechanisms involved.
  21. [21]
    https://pmc.ncbi.nlm.nih.gov/articles/PMC2672789/
  22. [22]
    Molecular pathogenesis of emphysema - PMC - NIH
    Feb 1, 2008 · This review examines the concept of a homeostatically active lung structure maintenance program that, when attacked by proteases and oxidants, leads to the ...Animal Models Of Emphysema · Adaptive Immunity In... · No Vegf, No Growth -- Only...
  23. [23]
    https://pmc.ncbi.nlm.nih.gov/articles/PMC2214683/
  24. [24]
    Cellular and Connective Tissue Changes in Alveolar Septal Walls in ...
    Jun 10, 1997 · Emphysema is commonly defined as enlargement of airspaces distal to terminal bronchioles accompanied by destruction of alveolar walls, ...
  25. [25]
    Imaging of pulmonary emphysema: A pictorial review - PMC
    Among these changes, destruction of the lung parenchyma is commonly referred to as pulmonary emphysema, defined as “an abnormal permanent enlargement of the air ...
  26. [26]
    Capillary structure in elastase-induced emphysema - PMC - NIH
    The essential component of pulmonary emphysema is destruction of alveoli. Because capillaries make up much of the alveolar wall, it has been a long-held opinion ...Abstract · Full Text · Selected References<|control11|><|separator|>
  27. [27]
    Lung volume reduction for severe emphysema: do we need a ... - NIH
    Lungs in an emphysematous patient, therefore, tend to remain inflated with overexpansion of the thoracic cage and flattening of the diaphragm. Patients are ...
  28. [28]
    Hypoxemia in patients with COPD: cause, effects, and disease ...
    Ventilation/perfusion mismatch resulting from progressive airflow limitation and emphysema is the key driver of this hypoxia, which may be exacerbated by ...
  29. [29]
    Diffusing capacity in chronic obstructive pulmonary disease ...
    Dec 2, 2021 · Airflow limitation is the basic characteristic of COPD, and correlates with the reduction in the FEV1 and FEV1/FVC ratio. The peripheral ...
  30. [30]
    Pulmonary function testing in COPD: looking beyond the curtain of ...
    May 7, 2021 · In principle, a low DLCO is indicative of the emphysematous phenotype of COPD. In these patients, rapid lung function decline is independently ...
  31. [31]
    Pulmonary Diseases - How Tobacco Smoke Causes Disease - NCBI
    Notably, cigarette smoking has very strong oxidant potential in that both the gas and tar phases contain high concentrations of free radicals (Repine et al.
  32. [32]
    Chemicals in Tobacco Products and Your Health - FDA
    May 1, 2020 · Cigarettes contain a mix of over 7000 chemicals. Some of the same chemicals are in other tobacco products. What are they and how can they ...
  33. [33]
    Chemistry and Toxicology of Cigarette Smoke and Biomarkers of ...
    Researchers have estimated that cigarette smoke has 7,357 chemical compounds from many different classes (Rodgman and Perfetti 2009).Introduction · Chemistry · Biomarkers · Summary
  34. [34]
    Oxidative stress and redox regulation of lung inflammation in COPD
    Oxidants present in cigarette smoke can stimulate alveolar macrophages to produce ROS and to release a host of mediators, some of which attract neutrophils ...<|separator|>
  35. [35]
    Mechanisms of cigarette smoke-induced COPD: insights from ...
    These observations lead to the idea that smoke evokes an inflammatory cell reaction and that these cells release proteases that overwhelm the antiproteolytic ...
  36. [36]
    Neutrophil Elastase Contributes to Cigarette Smoke-Induced ... - NIH
    According to the “elastase:antielastase” hypothesis, cigarette smoke causes inflammation and subsequent release of proteolytic enzymes into the lung in excess ...
  37. [37]
    Effects of smoking on disease risk among South Korean adults
    However, OR for COPD among the combined group of smokers with ≥20 pack-year smoking history was significantly higher, which was 3.92 (95% CI: 1.30–11.81), ...Methods · Statistical Analyses · Results
  38. [38]
    Secondhand smoke exposure and the risk of COPD
    Jun 7, 2023 · Figure 2 showed that SHS exposure was associated with an increased risk of COPD (odds ratio (OR): 2.25, 95% CI: 1.40–3.62, I2 = 98%, p < 0.01 ...
  39. [39]
    50-Year Trends in Smoking-Related Mortality in the United States
    Jan 24, 2013 · The disease risks from cigarette smoking increased over most of the 20th century in the United States as successive generations of first male ...
  40. [40]
    Achievements in Public Health, 1900-1999: Tobacco Use - CDC
    Nov 5, 1999 · The percentage of adults who never smoked increased from 44% in the mid-1960s to 55% in 1997. In 1998, tobacco use varied within and among ...Missing: WWII emphysema surge
  41. [41]
    Smoking reduction and the rate of decline in FEV 1 - ERS Publications
    Lung Health Study participants who quit smoking but occasionally relapsed (intermittent quitters) showed significant improvement in their rate of lung function ...
  42. [42]
    Alpha1-Antitrypsin (AAT) Deficiency - Medscape Reference
    May 29, 2024 · AATD is caused by mutations in the SERPINA1 gene located in the long arm of chromosome 14. ... AATD is a relatively common genetic condition, ...
  43. [43]
    Alpha-1 Antitrypsin Deficiency - StatPearls - NCBI Bookshelf - NIH
    The most common deficient allele associated with emphysema is the Z allele, which is present in approximately 2% to 3% of the white population in the United ...
  44. [44]
    Alpha-1 antitrypsin deficiency: MedlinePlus Genetics
    Sep 15, 2021 · This disorder affects about 1 in 1,500 to 3,500 individuals with European ancestry. It is uncommon in people of Asian descent. Many individuals ...
  45. [45]
    Genes and COPD - PMC - NIH
    The only known genetic risk factor for COPD, severe alpha 1 antitrypsin (AAT) deficiency, explains only 1–2% of cases of this disease.
  46. [46]
    Mechanisms of emphysema in α1-antitrypsin deficiency: molecular ...
    Pathogenic mutations block secretion of synthesised α1-AT to cause the observed deficiency of circulating protein 17. The observation that deficiency of a major ...
  47. [47]
    American Journal of Respiratory and Critical Care Medicine
    The pathogenesis of pulmonary emphysema in AAT deficiency and as a consequence of cigarette smoking in individuals with normal levels of AAT has been postulated ...
  48. [48]
    Genetics of COPD and Emphysema - PMC - NIH
    Variations in several genes including interleukin-1019 and tumor necrosis factor (TNF)-α20 have been purported to modify the development of COPD in individuals ...
  49. [49]
    Association Between TNF-α-308, +489, −238 Polymorphism, and ...
    As smoking is the major risk factor for the development of COPD, this sub-group analysis illustrates the additional information genetic polymorphism provides ...
  50. [50]
    polygenic risk scores in population-based and case-control cohorts
    A risk score comprised of genetic variants can identify a small subset of individuals at markedly increased risk for moderate-to-severe COPD.
  51. [51]
    Alpha-1 Antitrypsin Deficiency Clinical Practice Guidelines
    Recommendation 1a: All individuals with COPD, regardless of age or ethnicity, should be tested for AATD (strong recommendation, moderate quality of evidence).
  52. [52]
    Pathogenesis and management of emphysema in people with HIV
    Emphysema has been identified among people with HIV (PWH) and has been associated with increased mortality. Smoking cessation is key to risk reduction.
  53. [53]
    Post-tuberculosis lung disease and chronic obstructive pulmonary ...
    Scarring, fibrosis, and residual "healed" granulomas are common findings frequently associated with calcification, while some patients may show bronchiectatic ...Missing: etiology | Show results with:etiology
  54. [54]
    Rheumatoid arthritis-associated lung disease - PMC - PubMed Central
    Combined pulmonary fibrosis and emphysema (CPFE) has also been demonstrated on HRCT scans in patients with rheumatoid arthritis.
  55. [55]
    Radiation-Induced Lung Injury—Current Perspectives and ... - NIH
    Tumor-related factors: Higher rates of organizing pneumonia have been observed in women with breast cancer treated with concurrent radiation and endocrine ...
  56. [56]
    Panlobular pulmonary emphysema caused by i.v. injection of ...
    Ritalin lung. November 11, 2018. Screening for Lung Cancer: Incidental Pulmonary Parenchymal Findings. December 12, 2017 | American Journal of Roentgenology ...
  57. [57]
    Congenital Lobar Emphysema - StatPearls - NCBI Bookshelf - NIH
    Jul 19, 2024 · This condition, also known as congenital lobar overinflation, primarily results from defective bronchial cartilage. CLE typically presents with ...Continuing Education Activity · Etiology · Evaluation · Treatment / Management
  58. [58]
    GOLD in Practice: Chronic Obstructive Pulmonary Disease ...
    Feb 12, 2021 · The modified Medical Research Council (mMRC) dyspnea scale comprises five statements that describe a range of dyspnea effects in increasing ...
  59. [59]
    COPD exacerbations: defining their cause and prevention - PMC
    Definition. An exacerbation of COPD is described as an acute worsening of respiratory symptoms associated with a variable degree of physiological deterioration.
  60. [60]
    Prevent a COPD Exacerbation or Flare Up
    Jul 31, 2025 · A COPD exacerbation or flare up is a sudden worsening of symptoms. These signs or symptoms are worse than your normal symptoms and may last 2 days or more.
  61. [61]
    Global Initiative for Chronic Obstructive Lung Disease 2023 Report
    The FEV1 also serves to determine the severity of airflow obstruction (GOLD grades 1, 2, 3, 4 or mild, moderate, severe, and very severe). Yet, several ...
  62. [62]
    Pulmonary hypertension and chronic cor pulmonale in COPD - PMC
    This review focuses on new information about the pathogenesis and treatment of pulmonary hypertension in COPD including information derived from lung volume ...
  63. [63]
    Cor Pulmonale - StatPearls - NCBI Bookshelf
    Cor pulmonale can be defined as an alteration in the structure (eg, hypertrophy or dilatation) and function of the right ventricle (RV) of the heart.
  64. [64]
    “Cor pulmonale parvus” in chronic obstructive pulmonary disease ...
    The classic cardiovascular complication of chronic obstructive pulmonary disease (COPD) is cor pulmonale, or enlargement of the right ventricle (RV). Most ...
  65. [65]
    Cachexia in chronic obstructive pulmonary disease - PubMed Central
    Cachexia and muscle wasting are well recognized as common and partly reversible features of chronic obstructive pulmonary disease (COPD), adversely affecting ...
  66. [66]
    Factors contributing to muscle wasting and dysfunction in COPD ...
    COPD is often associated with muscle wasting and a slow-to-fast shift in fiber type composition resulting in weakness and an earlier onset of muscle fatigue.
  67. [67]
    Inflammation and Skeletal Muscle Wasting During Cachexia - PMC
    Cachexia development in COPD has also been associated with the presence of systemic inflammation. COPD patients with unintentional weight loss and skeletal ...
  68. [68]
    COPD and osteoporosis: links, risks, and treatment challenges - NIH
    Mar 29, 2016 · Osteoporosis and its related fractures are common and have significant impacts on quality of life and even respiratory function in patients with COPD.
  69. [69]
    Osteoporosis in Asthma and COPD - PMC - NIH
    Nov 29, 2023 · Higher risk of developing osteoporosis is evident in patients of chronic obstructive pulmonary disease in comparison to patients of asthma.
  70. [70]
    Fracture prevention in COPD patients; a clinical 5-step approach
    Although osteoporosis and its related fractures are common in patients with COPD, patients with increased fracture risk are poorly identified and undertreated.
  71. [71]
    Impact of fatigue in patients with chronic obstructive pulmonary ... - NIH
    Clinically significant fatigue is common among patients with COPD and is associated with an increased disease burden.Missing: reduced | Show results with:reduced
  72. [72]
    Evaluation of psychological and physiological predictors of fatigue in ...
    Oct 21, 2009 · Fatigue in COPD impairs functional status; however there are few studies examining mechanistic pathways of this symptom.<|control11|><|separator|>
  73. [73]
    Depression in COPD – management and quality of life considerations
    Depression is very common in COPD patients. Around 40% are affected by severe depressive symptoms or clinical depressions.Depression In Copd... · Prevalence And Co-Morbidity · Table 1
  74. [74]
    Anxiety and depression—Important psychological comorbidities of ...
    Hypoxia is an additional factor that may play a role in the development of depression in COPD. Low arterial oxygen saturation has been shown to be associated ...
  75. [75]
    Management of cardiovascular comorbidities in chronic obstructive ...
    In COPD patients, the risk of CVD is on average 2–3 times higher than in persons of comparable age in the general population, even when taking into account the ...
  76. [76]
    Defining the relationship between COPD and CVD - NIH
    CVDs are common in people with COPD, and their presence is associated with increased risk for hospitalization, longer length of stay and all-cause and CVD- ...
  77. [77]
    Prevalence and impact of diabetes, hypertension, and ... - NIH
    Chronic obstructive pulmonary disease (COPD) is associated with important chronic comorbid diseases, including diabetes, hypertension and cardiovascular ...
  78. [78]
    Comorbidities in Chronic Obstructive Pulmonary Disease - PMC - NIH
    Comorbidities such as cardiac disease, diabetes mellitus, hypertension, osteoporosis, and psychological disorders are commonly reported in patients with chronic ...
  79. [79]
    Comorbid Heart Disease in Patients with COPD is Associated with ...
    Jan 9, 2023 · Multimorbidity involving COPD and heart disease has been found to lead to a higher risk for hospitalization and mortality. COPD has been shown ...
  80. [80]
    Emphysema - Diagnosis and treatment - Mayo Clinic
    Nov 19, 2024 · The most important step in any treatment plan for emphysema is to quit all smoking. Stopping smoking can keep emphysema from getting worse and making it harder ...Missing: definition | Show results with:definition
  81. [81]
    Advances in imaging for lung emphysema - PMC - PubMed Central
    Imaging modalities in lung emphysema are manifold: computed tomography (CT) imaging is nowadays the gold standard.
  82. [82]
    Emphysema quantification using chest CT: influence of radiation ...
    Nov 7, 2018 · Computed tomography (CT) emphysema quantification is affected by both radiation dose (i.e. image noise) and reconstruction technique.
  83. [83]
    Pulmonary Function Tests - StatPearls - NCBI Bookshelf - NIH
    Restrictive ventilatory defects are characterized by a normal FEV1/FVC ratio (>0.70) and a reduction in TLC below the fifth percentile or 80% of the predicted ...
  84. [84]
    Spirometry Quick Guide - GOLD
    The spirometric criterion required for a diagnosis of COPD is an FEV1/FVC ratio below 0.7 after bronchodilator.<|control11|><|separator|>
  85. [85]
    Pulmonary function testing in COPD: looking beyond the curtain of ...
    May 7, 2021 · In the case of forced expiration, air trapping is reflected by an increase in the RV within a slightly preserved TLC. The RV/TLC ratio ...Pft Phenotyping Guides Copd... · Resting Lung Volumes And... · Diffusion Capacity
  86. [86]
    Pulmonary Function Test - Physiopedia
    Step 5: RV/TLC ratio (Normal range: <35% or < predicted). RV/TLC >35% or > predicted indicates Air trapping. Step 6: DLCO (Normal range: 80-120% of predicted).
  87. [87]
    Oxygen desaturation during the six-minute walk test in COPD patients
    A ≥ 4% decrease in SpO2 suggests significant desaturation and is used for assessing the need for oxygen supplementation in patients with chronic lung disease.
  88. [88]
    Prognostic Value of Desaturation during a 6-Minute Walk Test in ...
    Feb 14, 2003 · Desaturation was defined as a fall in oxygen saturation to 88% or less during the 6-minute walk test. Desaturation was common (44 of 83 usual ...METHODS · RESULTS · DISCUSSION
  89. [89]
    Changes in Forced Expiratory Volume in 1 Second over Time in COPD
    Sep 26, 2011 · The rate of change in FEV 1 among patients with COPD is highly variable, with increased rates of decline among current smokers, patients with bronchodilator ...
  90. [90]
    Lung function decline in COPD - PMC - NIH
    In emphysematous COPD patients with the PiZ phenotype, the mean annual FEV1 decline was higher in moderate disease, corresponding to GOLD stage II, and was ...
  91. [91]
    Decline in FEV1 in Relation to Incident Chronic Obstructive ...
    Jul 2, 2009 · Mean decline in FEV1 among the incident cases was 51 ml/year (mild COPD 43 ml/year, moderate COPD 54 ml/y and severe COPD 102 ml/y) ...Results · Changes In Lung Function And... · Decline In Fev Among...<|separator|>
  92. [92]
    Distinguishing among asthma, chronic bronchitis, and emphysema
    The history holds the central role in distinguishing among asthma, chronic bronchitis, and emphysema. A personal or family history of atopy, ...<|control11|><|separator|>
  93. [93]
    Heart failure and chronic obstructive pulmonary disease - NIH
    The difficulty in differentiating between HF and chronic obstructive pulmonary disease symptoms and signs is illustrated in a single cohort study comparing the ...
  94. [94]
    Centrilobular pulmonary emphysema | Radiology Reference Article
    Jul 3, 2025 · Early centrilobular emphysema is usually seen as small (<1 mm to 3 cm), round, evenly distributed lucencies with ill-defined borders that may ...Missing: pathogenesis | Show results with:pathogenesis
  95. [95]
    Emphysema: Background, Pathophysiology, Etiology
    Apr 26, 2024 · Approximately 14.2 million Americans (6.4%) in 2021 reported that they were diagnosed with COPD, however the actual number is likely much higher ...Background · Pathophysiology · Etiology · Epidemiology<|control11|><|separator|>
  96. [96]
    Pulmonary Emphysema Subtypes on Computed Tomography in ...
    The estimated population prevalence of emphysema was 27% (95%CI:21–32%), with centrilobular-predominant emphysema being most common (14%; 95%CI:10–18%), ...
  97. [97]
    Paraseptal Emphysema: From the Periphery of the Lobule to the ...
    Sep 15, 2020 · CT studies have demonstrated that the prevalence of paraseptal emphysema ranges from 3% in community-dwelling subjects to 15% in smokers with ...Missing: pathogenesis | Show results with:pathogenesis
  98. [98]
    Bullous Emphysema - StatPearls - NCBI Bookshelf
    Apr 12, 2025 · Bullous emphysema is a form of COPD characterized by airflow limitation due to irreversible destruction and enlargement of alveolar spaces beyond the terminal ...
  99. [99]
    Bullous Disease of the Lung | Thoracic Key
    Jan 11, 2017 · A bulla is an air-containing space within the lung parenchyma that arises from destruction, dilatation, and confluence of airspaces distal to terminal ...
  100. [100]
    Emphysema - Radiology Key
    Jul 21, 2019 · Paracicatricial Emphysema. Lung destruction, and therefore emphysema, is commonly found adjacent to areas of scarring, which explains the ...
  101. [101]
    Computed Tomography of Contemporary Occupational Lung Disease
    Aug 16, 2024 · In this review, we will share our approach to the diagnosis of occupational lung disease with a focus on the imaging features that best assist the radiologist ...
  102. [102]
    The Pathology of Chronic Obstructive Pulmonary Disease: Progress ...
    Dec 1, 2016 · There are 4 main types of emphysema: proximal acinar emphysema (including the centriacinar emphysema seen characteristically in cigarette ...
  103. [103]
    Full article: Phenotypes of Chronic Obstructive Pulmonary Disease
    Jul 2, 2009 · Paracicatricial emphysema (Citation[219]) is not pertinent to radiographic phenotypes of COPD since it is secondary to underlying lung ...
  104. [104]
    A morphologic study of the airway structure abnormalities in patients ...
    Irregular (paracicatricial) emphysema was identified by the presence of emphysema adjacent to areas of parenchymal distortion. Figure 3 Manifestation of ...
  105. [105]
    Emphysema Imaging: Practice Essentials, Radiography, Computed ...
    Mar 31, 2023 · High-resolution CT (HRCT) shows enlarged air-spaces or bullae adjoining pulmonary scars, consistent with paracicatricial emphysema. Red mark ...Missing: pathogenesis | Show results with:pathogenesis
  106. [106]
    Imaging of Emphysema: A Comprehensive Review - IntechOpen
    The two main techniques used to quantify the extent of emphysema on CT are the threshold technique and histogram analysis. These are based on the simple fact ...
  107. [107]
    Lung Emphysema - an overview | ScienceDirect Topics
    Unless large areas of paracicatricial emphysema exist, there are usually no symptoms or major problems associated with the disorder. Most pathophysiological ...
  108. [108]
    Alpha-1 Antitrypsin Deficiency - GeneReviews® - NCBI Bookshelf
    Oct 27, 2006 · PI*ZZ. Individuals with this genotype have a serum concentration of AAT that is approximately 10%-20% of normal (serum levels of 20-35 mg/dL) ...
  109. [109]
    Alpha-1 antitrypsin deficiency: an update on clinical aspects of ... - NIH
    Oct 28, 2020 · AATD lung disease is characterized by basal pan-lobular emphysema at an early age, though a range of other phenotypes have been recognized ( ...
  110. [110]
    Alpha-1 Antitrypsin Deficiency: Phenotypes and Quality of Life
    Jul 15, 2015 · It is classically considered to be associated with early-onset and rapidly progressive lower zone panlobular emphysema (1).
  111. [111]
    Smoking, lung function, and alpha 1-antitrypsin deficiency - PubMed
    Jan 19, 1985 · Mean age of onset of dyspnoea in smokers (32 years) was significantly lower than that in non-smokers (51 years).
  112. [112]
    Lung disease in never-smokers with severe α1-antitrypsin deficiency
    Longitudinal studies have shown that smokers with severe AATD (PI*ZZ) develop emphysema earlier than non-deficient smokers, starting from the age of 35–40 ...
  113. [113]
    Alpha-1-Antitrypsin Deficiency Targeted Testing and Augmentation ...
    Jan 27, 2025 · Alpha-1-antitrypsin (A1AT) deficiency is a common hereditary disorder associated with increased risk of developing chronic obstructive ...
  114. [114]
    Alpha-1 antitrypsin deficiency: An underrecognized, treatable cause ...
    Jul 1, 2016 · Available blood tests for alpha-1 antitrypsin deficiency include: The serum alpha-1 antitrypsin level, most often done by nephelometry. Normal ...
  115. [115]
    Decline in FEV1 related to smoking status in individuals with severe ...
    Severe alpha1-antitrypsin (AAT) deficiency predisposes to emphysema development. Highly variable rates of decline in lung function are reported in PiZZ ...
  116. [116]
    Prevalence of emphysema in people living with human ...
    Studies from the EXHALE cohort found the prevalence of emphysema to be 27, 31, and 33% in PLWH, whereas the prevalence of emphysema in controls was 15% (16) (p ...
  117. [117]
    Interactions between HIV infection and chronic obstructive ...
    Sep 1, 2011 · The authors confirmed the higher incidence of emphysema associated with HIV infection (15% versus 2%, p = 0.025).
  118. [118]
    Recent Advances in HIV-Associated Chronic Lung Disease Clinical ...
    PWH were at 4-fold higher risk for emphysema than uninfected controls, with 18% of these PWH lifelong non-smokers having emphysema, compared to 4% of controls.<|control11|><|separator|>
  119. [119]
    Increased Risk of Radiographic Emphysema in HIV Is Associated ...
    The association of HIV with emphysema appears mediated by elevated sCD14 levels, suggesting an important role for immune activation in emphysema pathogenesis in ...Missing: etiology | Show results with:etiology
  120. [120]
    Activation-induced Cell Death Drives Profound Lung CD4+ T ... - NIH
    Measurements and Main Results: HIV+COPD+ individuals demonstrated profound CD4+ T-cell depletion with reduced CD4/CD8 T-cell ratios in bronchoalveolar lavage– ...
  121. [121]
    COPD in People with HIV: Epidemiology, Pathogenesis ...
    Nov 29, 2023 · Factors contributing to this HIV-associated difference include chronic immune activation and inflammation, accelerated aging, a predilection for ...
  122. [122]
    A Low Peripheral Blood CD4/CD8 Ratio Is Associated with ... - NIH
    Jan 25, 2017 · A low CD4/CD8 ratio was associated with emphysema and low DLCO in HIV+ subjects, independent of other risk factors and clinical markers of HIV.Missing: dysregulation | Show results with:dysregulation<|control11|><|separator|>
  123. [123]
    Will expanded ART use reduce the burden of HIV-associated ...
    While the best-established COPD risk factor is cigarette smoking, emerging data suggest HIV infection also independently increases COPD risk. The purpose of ...
  124. [124]
    Pulmonary Disease in HIV-Infected Adults in the Era of Antiretroviral ...
    Finally, a recent HIV emphysema study found that low CD4/CD8 ratio (<0.4), associated with chronic inflammation and T-cell activation in HIV, was independently ...Missing: dysregulation | Show results with:dysregulation
  125. [125]
    HIV-associated Obstructive Lung Diseases - PMC - NIH
    Jun 1, 2014 · However, data from Diaz and colleagues demonstrated that emphysema was an important determinant of a decreased DLCO.Missing: tolerance | Show results with:tolerance
  126. [126]
    Influence of Impaired Diffusing Capacity and Sleep-disordered ...
    Impaired DlCO contributes to daytime hypoxemia and can impair exercise capacity, decrease quality of life, and increase cardiopulmonary morbidity and mortality ...Missing: tolerance | Show results with:tolerance<|control11|><|separator|>
  127. [127]
    Pulmonary Effects of IV Injection of Crushed Oral Tablets: “Excipient ...
    Ritalin lung is the basal-predominant panlobular emphysema caused by injection of methylphenidate (Ritalin) tablets, which contain talc [7, 14, 17] (Fig. 3).
  128. [128]
    Recreational Drug–induced Cardiopulmonary Injury | RadioGraphics
    Sep 18, 2025 · The exact pathogenesis of emphysema in Ritalin lung remains unclear ... Panlobular pulmonary emphysema caused by I.V. injection of ...E-Cigarette Use Or... · Cocaine · Intravenous Drug Use
  129. [129]
    Severe precocious emphysema in intravenous methylphenidate ...
    Intravenous (IV) drug abuse is known to cause pulmonary tale granulomatosis. Reports have documented a syndrome of pulmonary vascular sclerosis in long-term ...
  130. [130]
    https://pubs.rsna.org/doi/10.1148/rg.250013
  131. [131]
    Syndrome of Combined Pulmonary Fibrosis and Emphysema
    CPFE is reported in 26–54% of patients with idiopathic interstitial pneumonia (35, 36), with higher prevalence in those requiring hospital admission (45–71%) ( ...
  132. [132]
    Combined Pulmonary Fibrosis and Emphysema: When Scylla ... - NIH
    Apr 28, 2023 · The complex pathology of this condition involves emphysematous destruction of lung parenchyma, diffuse interstitial fibrosis, changes in the ...3. Pathophysiology · 3.3. Histopathology · 3.3. 3. Pulmonary...
  133. [133]
    Combined Pulmonary Fibrosis and Emphysema (CPFE) Clinical ...
    Jan 28, 2021 · Combined pulmonary fibrosis and emphysema (CPFE) is an underrecognized syndrome characterized by chronic, progressive disease with a dismal prognosis.
  134. [134]
    Swyer-James-MacLeod Syndrome - StatPearls - NCBI Bookshelf - NIH
    May 1, 2023 · Swyer-James-MacLeod syndrome is a rare lung disorder characterized by a reduction in the pulmonary vasculature and alveolar hyperdistention.Pathophysiology · Evaluation · Treatment / Management · Differential Diagnosis
  135. [135]
    Spectrum of manifestations of Swyer-James-MacLeod syndrome
    Purpose: The clinical and imaging findings of children with Swyer-James-MacLeod syndrome (SJMS) were reviewed to determine the incidence and type of ...Missing: etiology prevalence
  136. [136]
    Swyer–James–MacLeod syndrome—a rare diagnosis presented ...
    Jun 16, 2017 · The prevalence is estimated to be 0.01% based on a survey of 17,450 chest radiographs 3. It is often misdiagnosed as chronic obstructive ...Missing: etiology features
  137. [137]
    Congenital lobar emphysema: diagnosis and treatment options - NIH
    May 1, 2019 · Congenital lobar emphysema (CLE) is a rare developmental lung malformation. During the third week of gestation, the development of the ...
  138. [138]
    [Polyalveolosis: pathogenesis of congenital lobar emphysema?]
    Background: Congenital lobar emphysema is an unusual condition and its pathogenesis remains unknown. The variety of findings in pathology studies of the ...
  139. [139]
    Managing Congenital Lobar Overinflation Associated with ...
    Aug 28, 2020 · Intrinsic causes of CLO include bronchial structural abnormalities or developmental deficiencies in bronchial cartilage, and extrinsic ...
  140. [140]
    Congenital lobar emphysema in bilateral lung lobes: a case report
    CLE is a rare disease of the lung with an incidence of about 1 per 20,000 to 30,000 births (4). ... Congenital lobar emphysema: experience with 21 cases. Pediatr ...
  141. [141]
    Two further cases supporting nonsurgical management in ... - PubMed
    Conservative treatment of children with congenital lobar emphysema is an attractive option, whenever justifiable on medical grounds.
  142. [142]
    Chronic obstructive pulmonary disease c 2: Pathology and biochemistry of emphysema - PMC
    ### Summary of Focal Emphysema from "Chronic obstructive pulmonary disease c 2: Pathology and biochemistry of emphysema" by J. Hogg and R. Senior
  143. [143]
    Emphysema - Lung - Pathology Outlines
    Centriacinar, centrilobular or proximal acinar emphysema (mostly associated with smoking and COPD); Panacinar or panlobular emphysema; Paraseptal or distal ...Missing: pathogenesis induced
  144. [144]
    16 Lungs | Radiology Key
    Jul 6, 2020 · Compensatory emphysema is evident in the remaining lung after lobectomy or due to lobular atelectasis. Other causes of unilateral ...<|control11|><|separator|>
  145. [145]
    Compensatory Emphysema - MalaCards
    Compensatory emphysema is a condition in which one portion of the lung increases in size and function, when another portion is destroyed or temporarily useless.Missing: post- definition
  146. [146]
    Emphysema in asymptomatic smokers: Quantitative CT evaluation in ...
    Ormitti, et al. Early smoking-induced lung lesions in asymptomatic subjects. Correlations between high-resolution dynamic CT and pulmonary function testing.Missing: causes | Show results with:causes
  147. [147]
    Pulmonary emphysema | Radiology Reference Article
    Mar 22, 2025 · paracicatricial emphysema · localized emphysema · idiopathic giant bullous emphysema (or vanishing lung syndrome). congenital lobar emphysema.Centrilobular emphysema · Paracicatricial emphysema · EmphysemaMissing: pathogenesis prevalence
  148. [148]
    Geriatric Chest Imaging: When and How to Image the Elderly Lung ...
    The finding of senile emphysema is usually not accompanied by the clinical findings of chronic obstructive pulmonary disease like cough and sputum production.
  149. [149]
    Pneumothorax in patients with COPD and emphysema receiving ...
    Jan 2, 2023 · Emphysema is a widely known risk factor of pneumothorax in patients with COPD, caused by rupture of bullae or blebs. Our described cases raise ...
  150. [150]
    The risk of secondary spontaneous pneumothorax in patients with ...
    May 17, 2024 · Our study revealed an elevated risk of SSP in patients with COPD. It has also been suggested that COPD patients with comorbidities, ...
  151. [151]
    Pneumonia in Patients with Chronic Obstructive Pulmonary Disease
    COPD patients may be more susceptible to develop pneumonia based on their clinical characteristics such as having chronic bronchitis with persistent mucus ...
  152. [152]
    Immune Dysfunction in Patients with Chronic Obstructive Pulmonary ...
    In this review, we discuss the role of immune dysfunction in COPD that may contribute to recurrent respiratory infections and disease severity.<|separator|>
  153. [153]
    Acute exacerbations of chronic obstructive pulmonary disease
    Exacerbations stud the course of COPD. Their frequency is variable, averaging 1-2 per year. Their frequency generally increases with COPD severity.
  154. [154]
    Frequency and Severity of Exacerbations of COPD Associated ... - NIH
    Mar 3, 2022 · Between 30% and 50% of people with COPD experience at least one exacerbation per year. Even a single moderate exacerbation increases risk of ...
  155. [155]
    Pulmonary Hypertension Secondary to COPD - PubMed Central - NIH
    The increased RVEDV in cor pulmonale induces a shift of the interventricular septum into the LV and decreases LV diastolic compliance but this does not ...
  156. [156]
    Treatment of respiratory failure in COPD - PMC - PubMed Central
    Functional failure of the lung itself (type I respiratory failure) primarily results in arterial hypoxemia, associated with normal or even reduced levels of ...
  157. [157]
    Development and Relevance of Hypercapnia in COPD - PMC
    Feb 22, 2021 · Conversely, the classical cachectic “pink puffer” with emphysema has long been thought more likely to have type 1 not type 2 respiratory failure ...
  158. [158]
    Osteoporosis in COPD patients: Risk factors and pulmonary ... - NIH
    Patients with chronic obstructive pulmonary disease have a high prevalence of osteoporosis and a high risk of fracture.Missing: complications | Show results with:complications
  159. [159]
    Chronic obstructive pulmonary disease and atherosclerosis
    Mar 23, 2022 · Atherosclerosis drastically impairs blood flow and oxygen availability to tissues, leading to life-threatening outcomes including myocardial ...
  160. [160]
    Sarcopenia and cachexia: the adaptations of negative regulators of ...
    Muscle wasting should be considered a serious complication of COPD that has important implications for survival. Systemic inflammation, i.e., increased muscle ...
  161. [161]
    Associations between depression and anxiety index and frequency ...
    Dec 18, 2023 · Depression and anxiety have reported prevalence rates of approximately 25% and 40% in COPD, and prevalence may be associated with younger age, ...
  162. [162]
    Effect of Emphysema on Lung Cancer Risk in Smokers - NIH
    Emphysema (≥5% on CT) was found to be associated with a 3.8-fold increased lung cancer risk in Caucasians, with higher risk in subgroups of younger (<65 years ...Results · Subject Characteristics · DiscussionMissing: response | Show results with:response
  163. [163]
    Improved patient outcome with smoking cessation: when is it too late?
    In contrast, those who continued to smoke experienced an FEV1 decline of 63 mL/year. Thus, smoking cessation nearly halved the rate of descent in FEV1 in ...
  164. [164]
    Comprehensive pulmonary rehabilitation according to severity of ...
    The 6 MWD in patients in three stages of COPD was increased after PR up to approximately 50 m, which could not be explained by only the learning effect. However ...
  165. [165]
    Pulmonary Rehabilitation Improves Outcomes in Chronic ... - NIH
    Similar quartiles were assessed for FEV1 percent predicted as well as the 6-minute-walk distance (6MWD). The primary outcome was the change in quality of life ...
  166. [166]
    Nutritional support in chronic obstructive pulmonary disease (COPD)
    There is good evidence that nutritional support, in the form of oral nutritional supplements (ONS), can overcome energy and protein imbalances.
  167. [167]
    Targeted medical nutrition for cachexia in chronic obstructive ...
    Targeted medical nutrition containing high‐dose omega‐3 fatty acids, vitamin D, and high‐quality protein is well tolerated with a good safety profile.Missing: management | Show results with:management
  168. [168]
    Prevalence of influenza and pneumococcal vaccination in chronic ...
    Our findings have proven that influenza and pneumococcal vaccination is associated with a decreased risk of acute exacerbations among patients with COPD, ...
  169. [169]
    Efficacy of Influenza and Pneumococcal Vaccination in Preventing ...
    Influenza vaccine and pneumococcal vaccine have demonstrated decrease in infective exacerbations in this population.
  170. [170]
    Oxygen therapy for COPD - PMC - PubMed Central
    A larger 2-year study of patients with COPD and modest daytime hypoxaemia [PaO2 56-59 mmHg (7.4-7.8 kPa)] who desaturated to a pulse oximeter oxygen saturation ...
  171. [171]
    Long-term Oxygen Treatment in Chronic Obstructive Pulmonary ...
    Long-term oxygen treatment (LTOT) prolongs life in patients with chronic obstructive pulmonary disease (COPD) and severe resting hypoxemia.
  172. [172]
    [PDF] 2023 GOLD Pocket Guide
    suspected, pharmacotherapy should primarily follow asthma guidelines, but pharmacological and non- pharmacological approaches may also be needed for their COPD.
  173. [173]
    Chronic Obstructive Pulmonary Disease (COPD) Treatment ...
    Jul 7, 2025 · The mean 12-week predose FEV1 improvements vs placebo were 0.12 L, 0.07 L, and 0.11 L (P< 0.001) in the trials, with a 24-week improvement of ...<|control11|><|separator|>
  174. [174]
    Treatment with LABA versus LAMA for stable COPD: a systematic ...
    Apr 29, 2020 · Treatment with LAMA in stable COPD provided a significantly lower incidence of exacerbation and non-serious adverse events, and a higher trough FEV 1 compared ...
  175. [175]
    Dual LABA/LAMA Therapy versus LABA or LAMA Monotherapy for ...
    Dual LABA/LAMA therapy is superior to either LABA or LAMA monotherapy based on the reduced risk of exacerbations and hospitalizations.Methods · Results · Discussion
  176. [176]
    Rational use of inhaled corticosteroids for the treatment of COPD
    Jul 24, 2023 · The major clinical benefit of ICS in COPD is a ~25% reduction in exacerbations, observed in RCTs of patients with frequent or severe ...Ics Use In Asthma Versus... · Ics Monotherapy Vs. Placebo · Lama/laba/ics Vs. Lama/laba
  177. [177]
    Augmentation Therapy for α1 Antitrypsin Deficiency: A Meta-Analysis
    Jul 18, 2009 · The decline in FEV1 was slower by 23% (absolute difference, 13.4 ml/year; CI, 1.5 to 25.3 ml/year) among all patients receiving augmentation ...
  178. [178]
    Lung Volume Reduction Surgery - StatPearls - NCBI - NIH
    Aug 11, 2024 · Lung volume reduction surgery (LVRS) is a surgical procedure primarily used to treat patients with severe emphysema, a form of chronic obstructive pulmonary ...
  179. [179]
    lung volume reduction surgery (LVRS) - Henry Ford Health
    LVRS relieves this issue by removing 20 to 30 percent of the most diseased portion of the lung. ... Candidates for LVRS are people with severe or end-stage ...
  180. [180]
    A Randomized Trial Comparing Lung-Volume–Reduction Surgery ...
    After 24 months, exercise capacity had improved by more than 10 W in 15 percent of the patients in the surgery group, as compared with 3 percent of patients in ...
  181. [181]
    The National Emphysema Treatment Trial (NETT) | Part II
    Mar 13, 2011 · The 90-day mortality rate was 7.9% (95% confidence interval, 5.9–10.3%) in the LVRS group compared with 1.3% in the medical group (P < 0.001).
  182. [182]
    Patients at High Risk of Death after Lung-Volume–Reduction Surgery
    Lung-volume–reduction surgery is a potentially valuable treatment for patients with advanced emphysema. During the operation, 20 to 35 percent of the ...
  183. [183]
    Bullectomy for symptomatic or complicated giant lung bullae - PubMed
    Conclusions: Bullectomy improved pulmonary function in most patients with a symptomatic or complicated giant bulla, or both. However, increasing bulla size and ...
  184. [184]
    Survival benefit of lung transplantation compared with medical ...
    We conclude that transplant surgery has a survival benefit in the more severely affected end-stage COPD patients (with 6 MWD <1000 ft (∼300 m) or FEV1 <20%), ...
  185. [185]
    Lung transplantation for emphysema - Inci
    The median survival after either type of LT for patients with EMP was 5.0 years (95% CI: 4.8–5.2). The proportion of patients who had BLT increased from 21.6% ...
  186. [186]
    Lung transplantation for emphysema - PMC - NIH
    30-day, 1 year, and 5 years survival (%) in patients aged <50 years were 93.6, 80.2, and 43.6, respectively, for the SLT patients, and 94.9, 84.7, and 68.2, ...
  187. [187]
    Patient Selection for Bronchoscopic Lung Volume Reduction - PMC
    Apr 23, 2020 · Bronchoscopic lung volume reduction (BLVR) is a valuable treatment option for carefully selected patients with severe COPD.
  188. [188]
    A Multicenter Randomized Controlled Trial of Zephyr Endobronchial ...
    Mar 29, 2018 · Conclusions: Zephyr EBV provides clinically meaningful benefits in lung function, exercise tolerance, dyspnea, and quality of life out to at ...
  189. [189]
    Lung volume reduction with endobronchial coils for patients ... - NIH
    The most common complications of lung volume reduction coil treatment are: COPD exacerbations, pneumonia, Coil Associated Opacity and an increased risk of ...
  190. [190]
    Technology update: bronchoscopic thermal vapor ablation for ... - NIH
    BTVA is an effective treatment approach in patients with upper lobe-predominant emphysema. By inducing an inflammatory reaction, BTVA leads to fibrosis and ...
  191. [191]
    Endobronchial lung volume reduction with valves reduces ...
    Endobronchial valves reduce the number of exacerbations one year after ELVR. · Decrease of exacerbations is higher in patients with complete lobar atelectasis.
  192. [192]
    Stem cell therapies for chronic obstructive pulmonary disease
    Sep 19, 2024 · This review summarizes the characteristics of various stem cell types and describes their therapeutic potential in the treatment of COPD, with a particular ...<|separator|>
  193. [193]
    Mesenchymal Stem Cell Administration in Patients with Chronic ...
    All patients reported significant improvements in their emotional state and physical abilities. Improved lung function in these two advanced pulmonary emphysema ...
  194. [194]
    Stem Cell Therapy for COPD: Where are we?
    This included two phase II clinical trials. These trials were for 52 weeks and unfortunately did not show any significant benefit. More preclinical research ...
  195. [195]
    A Phase III Randomized, Multicenter Trial: RESPIRE Protocol
    Apr 16, 2024 · This article presents a study protocol to evaluate the efficacy of adipose-derived (AD) MSCs therapy in improving FEV-1 in COPD patients.
  196. [196]
    Novel Anti-Inflammatory Approaches to COPD - PMC
    Jun 29, 2023 · Lebrikizumab, a humanized mAb that binds to soluble IL-13 and inhibits activation of IL-4Rα and IL-13Rα1 heterodimers, has been examined in ...
  197. [197]
    Dupilumab for COPD with Type 2 Inflammation Indicated by ...
    Dupilumab, a fully human monoclonal antibody, blocks the shared receptor component for interleukin-4 and interleukin-13, key drivers of type 2 inflammation.
  198. [198]
    Emphysema Market Analysis Reveals Promising Growth ...
    Oct 21, 2025 · In March 2025, Japan approved DUPIXENT as the first biologic therapy for COPD, supported by positive outcomes from the Phase III BOREAS and ...
  199. [199]
    Unexpected Failure of Anti–Tumor Necrosis Factor Therapy in ...
    None of the current therapies have been shown to reduce the relentless progression of the disease and are poor at preventing exacerbations.
  200. [200]
    TNFα antagonists for acute exacerbations of COPD - PubMed
    Conclusions: Etanercept was not more effective than prednisone for treatment of acute exacerbations of COPD. Efficacy of prednisone was most apparent in ...
  201. [201]
    [PDF] The Role of Gene Therapy as an Emerging Treatment Strategy for ...
    Feb 19, 2025 · Overall,. AAV gene therapy holds the potential for treating AAT deficiency, but continuous studies are necessary to optimize its effectiveness ...
  202. [202]
    https://www.atsjournals.org/doi/10.1164/rccm.200702-253ED
  203. [203]
    Intrapleural Gene Therapy for Alpha-1 Antitrypsin Deficiency
    One strategy involves administration of an adeno-associated virus (AAV) gene therapy vector to the pleural space providing both local and systemic production of ...
  204. [204]
    A pilot study of all-trans-retinoic acid for the treatment of ... - PubMed
    Emphysema results from progressive destruction of alveolar septae and was considered irreversible until all-trans-retinoic acid (ATRA) was shown to reverse ...
  205. [205]
    https://www.astrazeneca.com/content/astraz/media-centre/press-releases/2025/update-on-resolute-phase-iii-trial.html
  206. [206]
    Randomised controlled trial for emphysema with a selective agonist ...
    The feasibility of using retinoids for the treatment of emphysema has been investigated in a short-term, placebo-controlled study (FORTE), funded through the ...
  207. [207]
    Post-COPD: Can Emphysema Be Repaired? - ATS Journals
    Sep 10, 2024 · The LEEP (Losartan Effects on Emphysema Progression) (37) and FORTE (Feasibility of Retinoid Therapy for Emphysema) (38) trials are two studies ...
  208. [208]
    Press Release: Itepekimab met the primary endpoint in one of two ...
    May 30, 2025 · The AERIFY-1 phase 3 study evaluating itepekimab in former smokers with inadequately controlled chronic obstructive pulmonary disease (COPD) met the primary ...Missing: emerging emphysema
  209. [209]
    Depemokimab for COPD: Phase 3 Clinical Trials Now Recruiting
    Jul 10, 2025 · Depemokimab is a long-acting interleukin-5 antagonist. The trial kicked off on June 23, 2025, and has an estimated primary completion currently ...Missing: emerging emphysema
  210. [210]
    Update on the RESOLUTE Phase III trial for FASENRA in chronic ...
    Sep 17, 2025 · FASENRA (benralizumab) is currently approved as an add-on maintenance treatment for adults with SEA in more than 80 countries, including the US, ...
  211. [211]
    Emerging Therapeutics in COPD: Mapping Innovation to Treatable ...
    Sep 3, 2025 · Tranilast, an anti-inflammatory and antifibrotic agent, has demonstrated protective effects against acute respiratory distress syndrome and ...
  212. [212]
    Understanding Emphysema Life Expectancy: A Comprehensive Guide
    While there is no definitive life expectancy, studies have shown average life expectancy rates for Stage 1, 2, 3, and 4 emphysema to be 9.7, 7.1, 6.1, and 3.4 ...
  213. [213]
    Finding the Best Thresholds of FEV 1 and Dyspnea to Predict 5-Year ...
    Feb 27, 2014 · Survival at 5 years was 0.89 for patients with FEV1≥70 vs. 0.46 in patients with FEV1 ≤35% (H.R: 6; 95% C.I.: 4.69–7.74). The new classification ...
  214. [214]
    Prognosis in End-Stage COPD | Palliative Care Network of Wisconsin
    Feb 20, 2025 · Poor prognostic factors include co-morbid illnesses, severity of illness (APACHE II score), low serum albumin, and/or low hemoglobin. Previous ...
  215. [215]
    The Body-Mass Index, Airflow Obstruction, Dyspnea, and Exercise ...
    Thus, the highest quartile (a BODE score of 7 to 10) was associated with a mortality rate of 80 percent at 52 months. These same data are shown in Figure 1B in ...Missing: emphysema | Show results with:emphysema
  216. [216]
    Panlobular emphysema is associated with COPD disease severity
    Panlobular emphysema is associated with greater degree of airflow obstruction and extent of emphysema, as well as increased respiratory symptoms, worse quality ...
  217. [217]
    Smoking Status and COPD – Symptoms and Prognosis
    However, it is not too late to quit smoking for patients with COPD, as former smokers have milder symptoms and a better prognosis compared to current smokers.Chronic Obstructive... · Copd And Smoking Status... · Risk Of Mortality At...
  218. [218]
    Chronic Obstructive Pulmonary Disease and Smoking Status - CDC
    Jun 21, 2019 · The age-adjusted prevalence of COPD was 15.2% among current cigarette smokers, 7.6% among former smokers, and 2.8% among adults who had never ...Missing: trends | Show results with:trends
  219. [219]
    Trends in the prevalence and incidence of chronic obstructive ... - NIH
    May 31, 2024 · Our findings indicate a rising prevalence of COPD among older adults in the United States since 2000, while the incidence rate of COPD has shown a declining ...Missing: anti- | Show results with:anti-
  220. [220]
    [PDF] Recommended Preventative and Control Measures to - OSHA
    Spirometry, or pulmonary function testing. (PFT), involves measuring the breathing ca- pacity of the lungs. It is particularly useful in.
  221. [221]
    More Stringent OSHA Standards Highlight PPE For Silica Dust
    Jun 16, 2021 · The key piece of PPE for silica dust revolves around providing a worker with a respirator that filters out particles. The National Institute for ...
  222. [222]
    How to protect workers from COPD: Overview - HSE
    Feb 13, 2025 · Use effective Local Exhaust Ventilation (LEV). Use respiratory protective equipment (RPE) when required. Don't forget that once it is in the air ...Missing: measures PPE emphysema
  223. [223]
    Occupational COPD—The most under‐recognized ... - NIH
    Cadmium exposure, know historically to induce emphysema, can activate MMP pathway and inflammation. Exposure to organic dust could induce inflammation through ...
  224. [224]
    Screening and Familial Testing of Patients for α1-Antitrypsin ...
    Early identification allows preventive measures to be taken, the most important of which is the avoidance of smoking (including the inhalation of second-hand ...
  225. [225]
    Air pollution and COPD: GOLD 2023 committee report
    Air pollution and mortality. Exposure to ambient PM2.5 was the fifth-ranking mortality risk factor in 2015. Deaths attributable to ambient PM2.5 increased ...
  226. [226]
    Improvement in household stoves and risk of chronic obstructive ...
    In summary, we found a substantial reduction in the risk of COPD after installation of chimneys on coal stoves in Xuanwei. This has broad implications because ...Missing: regulations | Show results with:regulations
  227. [227]
    Biomass Fuels and Respiratory Diseases | A Review of the Evidence
    Jul 17, 2007 · Improved stoves favor a more complete combustion of fuels, increasing the generated heat and decreasing the harmful by-products (high-efficiency ...Missing: regulations | Show results with:regulations
  228. [228]
    Screening for and early detection of chronic obstructive pulmonary ...
    Of 11 027 individuals screened, 24% presented with signs of airflow obstruction. These researchers concluded that spirometry screening of smokers older than 40 ...
  229. [229]
    Diagnosis and early detection of COPD using spirometry - PMC - NIH
    Spirometry testing should focus on those at risk particularly from smoking; thus spirometry was able to detect unrecognised airflow obstruction (FEV1 <80% ...Missing: preclinical | Show results with:preclinical
  230. [230]
    SCREENING OF SMOKERS BY SPIROMETRY FOR EARLY ...
    Present study evaluated the role of spirometric screening in early detection of COPD in chronic smokers. No such study has been conducted in our country.Missing: preclinical | Show results with:preclinical
  231. [231]
    The Clinical Definitions of Asthma - PMC - NIH
    It is believed that the term “asthma” was coined by Hippocrates around 450 bc. The term literally means “panting,” from the Greek.
  232. [232]
    Asthma History - News-Medical
    This Greek term means respiratory distress and panting. Hippocrates correlated the occurrence of asthma with environmental triggers.Asthma History: Ad · Asthma History: The Medieval... · Asthma History: Modern Day
  233. [233]
    The history of COPD - PMC - PubMed Central
    Some of the earliest references to the description of emphysema include: Bonet's description of “voluminous lungs” in 1679 (Bonet 1679); Morgagni's (1769) ...Missing: Hippocrates | Show results with:Hippocrates
  234. [234]
    History of Chronic Obstructive Pulmonary Disease - News-Medical
    Laënnec described emphysema of the lungs in 1821 in his Treatise of diseases of the chest. He was the inventor of the stethoscope who wrote that emphysema lungs ...Missing: descriptions Hippocrates
  235. [235]
    History of COPD: 1600s to the Present - Healthline
    Oct 17, 2017 · In 1821, the inventor of the stethoscope, physician René Laënnec, recognized emphysema as another component of COPD.Missing: descriptions Hippocrates
  236. [236]
    Understanding Early COPD - PMC - PubMed Central - NIH
    In 1821, though smoking was not common then, Laennec identified both characteristic features of what we now call COPD: emphysema and chronic bronchitis in ...
  237. [237]
    Early History of Chronic Obstructive Pulmonary Disease 1808–1980
    Sep 29, 2015 · The second major event was the first definitive evidence that smoking considerably increased mortality from chronic bronchitis and emphysema ( ...Before 1930 · 1930--1960 · Public Health And...<|separator|>
  238. [238]
    Chronic obstructive pulmonary disease past, present and future - PMC
    The ability to image the lung in vivo was realised when CT scanning was first applied to COPD, an area where conventional radiographic imaging had been ...Missing: NETT precursors
  239. [239]
    Does Protease–Antiprotease Imbalance Explain Chronic Obstructive ...
    Apr 7, 2015 · This review assesses the genetic evidence in support of protease–antiprotease imbalance in the pathogenesis of COPD. It also articulates why ...Epidemiology of COPD · Natural History of COPD · Emphysema in Alpha-1 Anti.
  240. [240]
    Genome-Wide Study of Percent Emphysema on Computed ...
    We report the first genome-wide association study to probe the genetics of quantitative emphysema on computed tomography in a general population sample. We ...Missing: 2020s | Show results with:2020s
  241. [241]
    FDA Approves Zephyr Endobronchial Valve for Treating Severe ...
    Jun 29, 2018 · First FDA-Approved Device for Emphysema Proven to Help Patients Breathe Easier and Enjoy More Active Lives. REDWOOD CITY, Calif.